Introduction {#s1}
============

Haploinsufficiency, or the inability to complete a cellular process with one functional allele of a given gene, manifests in tissue and organ defects with variable penetrance and severity ([@bib78]). For example, *Notch* (*N*) haploinsufficiency, which was discovered in *Drosophila*, causes a variety of tissue-specific defects including wing notching and extra sensory bristle formation that can vary greatly in penetrance and expressivity ([@bib53]). Notch pathway haploinsufficiency was subsequently observed in mammals, as *Notch1* heterozygous mice have heart valve and endothelium defects ([@bib59]), whereas *Notch2* heterozygotes have defects in bone, kidney and marginal zone B cells ([@bib33]; [@bib69]; [@bib79]). A single allele of *NOTCH2* or the *JAG1* ligand can also cause pathological phenotypes in humans, as heterozygosity of either gene can result in a variably penetrant developmental syndrome known as Alagille ([@bib50]; [@bib44]; [@bib61]). Thus, *Notch* gene dose sensitivity has been observed in a variety of Notch-dependent tissues in both humans and animals. Unfortunately, we currently lack a mechanistic understanding of what causes some tissues to be highly sensitive to *Notch* gene dose and what factors impact the variable penetrance and severity of *Notch* haploinsufficiency phenotypes.

Molecularly, Notch signaling is initiated by ligand-induced proteolysis of the Notch receptor to release the Notch intracellular domain (NICD) from the membrane ([@bib40]; [@bib7]). NICD subsequently transits into the nucleus, binds to the [C]{.ul}bf1/[S]{.ul}u(H)/[L]{.ul}ag1 (CSL) transcription factor (TF) and the adaptor protein Mastermind (Mam), and induces gene expression via two types of DNA binding sites: independent CSL sites that bind monomeric NICD/CSL/Mam (NCM) complexes, and [S]{.ul}u(H) [p]{.ul}aired [s]{.ul}ites (SPS) that are oriented in a head-to-head manner to promote cooperative binding between two NCM complexes ([@bib40]; [@bib7]). Once bound to an enhancer, the NCM complex activates transcription of associated genes via the P300 co-activator. Thus, the production of NICD is converted into changes in gene expression that ultimately regulate cellular processes during development.

Haploinsufficiency of Notch receptor and ligand encoding genes suggests that decreased gene dosage results in a sufficiently large decrease in NICD production to cause phenotypes in a subset of tissues. There is also growing evidence that genetic changes that reduce NICD degradation can alter signal strength with pathological consequences in specific cell types. In the mammalian blood system, for example, *Notch1* mutations that remove an NICD degron sequence have been associated with increased NICD levels and the development of T-cell Acute Lymphoblastic Leukemia (T-ALL) in mice and humans ([@bib60]; [@bib76]). Intriguingly, NICD turnover via this degron sequence has been directly linked to transcription activation, as the Mam protein interacts with the Cdk8 kinase module (CKM) of the Mediator complex, which can phosphorylate NICD to promote its ubiquitylation by the Fbxw7 E3-ligase and degradation by the proteasome ([@bib21]; [@bib20]). Accordingly, gene mutations that lower CKM activity have also been associated with increased NICD levels and T-ALL initiation and progression ([@bib45]). Thus, perturbations in mechanisms that regulate either NICD production or degradation can induce cell and/or tissue specific phenotypes.

In this study, we use *Drosophila* genetics, quantitative trait and expression analysis, and mathematical modeling to unravel a unique regulatory mechanism that impacts Notch signal strength in a tissue-specific manner. First, we unexpectedly found that an enhancer containing as few as 12 Notch dimer binding sites can induce tissue-specific phenotypes via a CKM-dependent mechanism that can be uncoupled from transcription activation. Second, based on our quantitative analysis and mathematical modeling, we show how changes in NICD degradation rates are predicted to preferentially impact long duration Notch-dependent processes, whereas genetic changes in NICD production rates (i.e. *Notch* haploinsufficiency) affect both short and long duration processes. Collectively, these findings provide new insights into how distinct Notch-dependent cellular processes can be differentially impacted by both enhancer architecture and signal duration to induce tissue-specific Notch defects within a complex animal.

Results {#s2}
=======

Enhancers with specific TF binding sites can induce a tissue-specific *Notch* phenotype {#s2-1}
---------------------------------------------------------------------------------------

To better understand transcriptional responses to *Notch* signals in *Drosophila*, we designed synthetic enhancers with comparable numbers of either CSL monomer or SPS dimer sites ([Figure 1A](#fig1){ref-type="fig"}; note, 1xSPS has the same number of sites as 2xCSL) ([@bib1]; [@bib55]; [@bib2]). We first tested the synthetic 1xSPS and 2xCSL sites for their ability to bind Notch/CSL/Mastermind (NCM) complexes in electromobility shift assays (EMSAs) using purified mouse (RBPJ, N1ICD1, and MAML1) and *Drosophila* (Su(H), NICD, and Mam) proteins. For this experiment, an equal amount of differentially labeled 2xCSL (IRdye-700, pseudo-colored magenta) and 1xSPS (IRdye-800, pseudo-colored green) probe was added into the same binding reaction containing different concentrations of the RBPJ/Su(H) TF with and without the species matched NICD/Mastermind co-activators ([Figure 1B--C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In the absence of co-activators, RBPJ and Su(H) bound each probe additively with both the mouse and fly proteins showing a slightly higher affinity to 2xCSL than 1xSPS (note, the increased unbound 1xSPS probe (green) in lane 4 of [Figure 1B](#fig1){ref-type="fig"} and lane 3 of [Figure 1C](#fig1){ref-type="fig"} relative to unbound 2xCSL probe (magenta)). Including the NICD/Mam co-activators didn't change the additive binding behavior of RBPJ and Su(H) to 2xCSL. By contrast, both the mouse and fly NCM complex preferentially filled both sites of the 1xSPS probe relative to 2xCSL ([Figure 1B--C](#fig1){ref-type="fig"}). Hence, these results demonstrate that while both the 2xCSL and 1xSPS synthetic sequences bind NCM complexes, only the 1xSPS sites mediate cooperative NCM complex binding.

![Synthetic Notch enhancers induce a *Drosophila* notched wing phenotype.\
(**A**) Sequences of 2xCSL and 1xSPS used for performing EMSAs and generating reporters. (**B--C**) Electromobility shift assays (EMSAs) using purified mammalian NCM proteins (**B**) and fly NCM proteins (**C**) with both 2xCSL (magenta) and 1xSPS (green) probes. Arrows highlight bands consistent with one vs two NCM complexes on DNA. RBPJ/Su(H) concentration increases from 10 to 320 nM and 1 µM NICD/Mastermind was used in indicated lanes. Note, we separated the 2xCSL and 1xSPS probe signals and show the EMSA data in grayscale in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. (**D--F**) Schematics of *6xSPS-3xGBE-lacZ* (*6SG*), *3xGBE-6xSPS-lacZ* (*G6S*) and *12xCSL-3xGBE-lacZ* (*12CG*). (**G--J**) Wings from flies with one copy, two copies, or 4 copies of *6SG-lacZ*, or 4 copies of *12CG-lacZ*. Arrowhead denotes a notch. (**K--L**) Quantified wing notching in flies with indicated transgenes. Proportional odds model tested penetrance and severity differences between *G6S-lacZ* and *G24S-lacZ*. Two-sided Fisher's exact test assessed the penetrance of other genotypes.](elife-53659-fig1){#fig1}

We next generated transgenic fly lines containing reporter genes with either CSL or SPS binding sites. Since prior studies found that including sites for the Grainyhead (Grh) pioneer TF enhanced Notch reporter activity ([@bib22]) and induced chromatin opening ([@bib34]), we generated fly lines containing CSL and SPS reporters with ([Figure 1D--F](#fig1){ref-type="fig"}) and without ([Figure 1---figure supplement 2B--C](#fig1s2){ref-type="fig"}) three copies of a [G]{.ul}rh [b]{.ul}inding [e]{.ul}lement (3xGBE). Surprisingly, flies homozygous for *6xSPS-3xGBE-lacZ* (*6SG-lacZ*) developed a notched-wing phenotype that mimics a classic *Notch* haploinsufficiency ([Figure 1H](#fig1){ref-type="fig"}). In contrast, flies homozygous for *3xGBE* alone (*G-lacZ*), *6xSPS* alone (*6S-lacZ*), or mutated SPSs (*6SmutG-lacZ*) ([@bib71]) inserted in the same locus were indistinguishable from wild type ([Figure 1---figure supplement 2A--C](#fig1s2){ref-type="fig"}). To define the *SPS-GBE* binding site features that contribute to wing notching, we tested additional fly lines and found that: i) The *6SG-lacZ* caused notched wings when inserted in another locus and regardless of the order of GBE and SPS, although with differences in penetrance and severity ([Figure 1---figure supplement 2D--H](#fig1s2){ref-type="fig"}); ii) The penetrance and severity of wing notching increased as a function of both transgene and SPS numbers ([Figure 1G--I and K](#fig1){ref-type="fig"}); and iii) Flies with an equal number of Notch monomer (CSL) sites next to 3xGBE did not develop notched wings ([Figure 1J and L](#fig1){ref-type="fig"}). In total, these findings show that adding as few as 12 GBE-associated SPSs into the genome is sufficient to induce a *Notch* haploinsufficiency phenotype in the wing.

To determine if the *6SG-lacZ* induced wing phenotype could be modified by genetic changes in *Notch* pathway components, we analyzed flies carrying different gene copy numbers of either *N* or the *Hairless* (*H*) co-repressor that antagonizes Notch-mediated gene activation ([@bib54]; [@bib4]). We found that a single *6SG-lacZ* transgene greatly enhanced the penetrance and severity of wing notching in *N* heterozygotes compared to either genotype alone ([Figure 2A--C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Moreover, adding two extra alleles of *N* (4N) or removing one allele of *H* significantly suppressed the notched wing phenotype induced by two copies of *6SG-lacZ* ([Figure 2D--H](#fig2){ref-type="fig"}). Thus, wing phenotypes induced by *6SG* can be enhanced or suppressed by changing the gene dose of *N* and *H,* respectively.

![*SPS-GBE* reporters impact wing margin and vein development but not macrochaetae.\
(**A--B**) Wings from *Notch* heterozygotes (*N^55e11/+^*) in the absence (**A**) and presence of *G6S-lacZ* (**B**). (**C**) Quantified wing notching in the indicated genotypes. Proportional odds model tested for penetrance/severity differences. (**D--E**) Wings from flies containing two extra *N* alleles (BAC{Notch-GFP-FLAG}) in the absence (**D**) and presence of *6SG-lacZ* (**E**). (**F**) Quantified wing notching in flies with indicated genotypes. Two-sided Fisher's exact test. (**G--H**) Wings from *H^1/+^* flies in the absence (**G**) and presence (**H**) of *6SG-lacZ*. Solid arrowhead highlights loss (**G**) and rescue (**H**) of L5 wing vein. Open arrowhead points to rescued *6SG*-induced wing notching phenotype in *H^1^*^/+^ flies. (**I**) Quantification of loss of L5 vein in flies with indicated genotypes. Each dot represents a measurement from an individual wing. Two-sided Student\'s t-test. In box plots, the line represents median, the box shows interquartile range, and whiskers represent the 1.5 times interquartile range. (**J--K**) Notum images from a *N^55e11/+^* (**J**) and *G6S-lacZ* (**K**) fly. Arrowhead denotes extra macrochaetae in *N^55e11/+^*. (**L**) Quantification of gained/lost dorsalcentral and scutellar macrochaetae (wild type = 8) in indicated genotypes. Proportional odds model tested for statistical significance. Data are mean ±95% confidence interval.](elife-53659-fig2){#fig2}

*N* and *H* haploinsufficiency also cause defects in macrochaetae bristle patterning ([@bib3]; [@bib68]) and wing vein development ([@bib16]). Intriguingly, *6SG-lacZ* did not significantly impact macrochaetae formation in either wild type or sensitized *N^+/-^* and *H^+/-^* backgrounds ([Figure 2J--L](#fig2){ref-type="fig"}). However, while flies carrying two copies of the *6SG-lacZ* Notch-dimer reporter alone did not cause a noticeable wing vein phenotype, two copies of the *6SG-lacZ*, but not the *12CG-lacZ* Notch-monomer reporter, did significantly suppress the loss of L5 wing vein observed in *H^+/-^* animals ([Figure 2G--I](#fig2){ref-type="fig"}). Altogether, these data demonstrate that coupled *SPS-GBE* sites affect a subset of dose sensitive phenotypes with wing margin cells being the most sensitive.

Cdk8 induces Notch turnover independent from transcription activation {#s2-2}
---------------------------------------------------------------------

Our findings raise two questions: How do the integrated *SPS-GBE* sites affect Notch activity, and why only in a subset of Notch-dependent processes? Prior studies have shown that Notch signal strength can be impacted by changes in either NICD production or degradation. Since NICD degradation in mammalian cells can be regulated by the Cdk8-Kinase module (CKM) that associates with the Mediator complex ([@bib45]; [@bib21]), we used genetics to assess the importance of the CKM in inducing wing phenotypes. To do so, we removed an allele of each gene of the Cdk8-kinase module (CKM; *cdk8* ([@bib47]), *cycC* ([@bib47]), *kto (Med12)* ([@bib70]), or *skd (Med13)* \[[@bib70]\]) or an allele of an E3-ligase that encodes the *Drosophila* homologue of *Fbxw7* (*archipelago, ago*) \[[@bib52]\]) and found that each significantly suppressed the penetrance and severity of 6SG-induced wing nicking ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Notably, we observed that in *N* heterozygotes, removing an allele of *cycC*, *kto*, *skd* or *ago*, but not *cdk8*, also significantly suppressed wing notching ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). These data are consistent with Cdk8 phosphorylating NICD to promote its ubiquitylation and degradation ([Figure 3C](#fig3){ref-type="fig"}; [@bib45]; [@bib21]). Moreover, the smaller effect of *cdk8* gene dose compared to changes of the other CKM genes is consistent with studies showing that *cdk8* is not thought to be the limiting factor in the formation of this Mediator submodule ([@bib14]; [@bib37]) and that enzymes are not typically gene dose sensitive ([@bib39]). Hence, these findings support the model that lowering the dose of key CKM genes in *Drosophila* slows NICD turnover and thereby rescues the wing notching phenotype observed in *6SG-lacZ* and *N* heterozygotes.

![Reducing the activity of the Cdk8-Mediator suppresses the formation of wing notches.\
(**A--B**) Quantified wing notching in *6SG-lacZ* (**A**) or *N^55e11/+^* (**B**) in *wild-type* or *cdk8*, *cycC*, *kto, skd* or *ago* heterozygotes. Proportional odds model with Bonferroni adjustment tested for significance compared to wild-type. (**C**) Model of Cdk8-mediated NICD degradation. NCM complexes on SPSs recruit Cdk8, CycC, kto and skd. Cdk8 phosphorylates NICD to promote its degradation via Ago and the proteasome (gray cylinder). Cdk8 can also interact with the core Mediator (gray oval). (**D**) Schematics of promoter-containing and -lacking transgenes at left. Wing notching penetrance and severity at right. Proportional odds model was used to assess significance. (**E**) Rbpj-N1ICD split luciferase assay assessing N1ICD half-life in HEK293T cells treated with DMSO or Actinomycin D. 95% confidence interval noted. (**F**) Western blot of N1ICD, total Notch1 and β-actin after Notch activation in mK4 cells treated with DMSO or Actinomycin D. (**G**) Rbpj-N1ICD split luciferase assay assessing N1ICD half-life in HEK293T cells treated with DMSO, 5 μM Senexin A or 10 μM Senexin A. 95% confidence interval noted. (**H**) Western blot of N1ICD and full-length Notch1 after Notch activation in either *wild-type* (OT13) or *Rbpj*-deficient (OT11) cells. Open arrow denotes post-translationally modified NICD and closed arrow denotes un-modified NICD.](elife-53659-fig3){#fig3}

The CKM has a complex relationship with promoter transcription ([@bib18]). Some studies suggest interactions between the CKM and the core Mediator occludes RNA polymerase recruitment ([@bib36]) and/or decreases transcription ([@bib62]), whereas other studies suggest Cdk8 stimulates transcription ([@bib23]; [@bib17]). To test the role of the transgene promoter in causing wing nicks, we analyzed flies with promoter-containing (*3xGBE-24xSPS-GFP, G24S-GFP*) or promoter-less transgenes (*3xGBE-24xSPS, G24S*) flanked by insulator sequences ([Figure 3D](#fig3){ref-type="fig"}). We found that the wing notching penetrance and severity was similar with both transgenes, and the wing phenotype generated by both was significantly suppressed by removing an allele of *skd* ([Figure 3D](#fig3){ref-type="fig"}). These findings suggest that a transcriptionally active promoter is not required to induce wing nicks.

To test the generality of the idea that transcription activation could be uncoupled from NICD degradation, we blocked transcription using actinomycin-D and assessed NICD half-life using a split-luciferase assay in HEK293T mammalian cells ([@bib31]). Importantly, we found that while actinomycin-D effectively inhibited Notch-induced transcription ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), it neither altered N1ICD half-life in the split-luciferase assay ([Figure 3E](#fig3){ref-type="fig"}), nor altered N1ICD mobility in western blot analysis ([Figure 3F](#fig3){ref-type="fig"}). These data suggest that post-translational modification and degradation of N1ICD does not require active transcription. In contrast, inhibiting Cdk8 activity using Senexin-A or SEL120-34A, two structurally distinct and specific inhibitors of Cdk8 and Cdk19, a closely related vertebrate paralogue that is absent in *Drosophila* ([@bib64]; [@bib66]), significantly prolonged N1ICD half-life in the split-luciferase assay ([Figure 3G](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Importantly, we found that N1ICD was stabilized in mammalian OT11 cells deficient for RBPJ ([Figure 3H](#fig3){ref-type="fig"}; [@bib35]), in mK4 cells deficient for the three Mastermind-like (MAML) proteins, and in mK4 cells treated with SEL120-34A ([Figure 3---figure supplement 2C--E](#fig3s2){ref-type="fig"}). These data suggest that N1ICD degradation is coupled with NCM complex formation on DNA and CDK8-mediated modification. Moreover, the increased N1ICD mobility observed in the absence of RBPJ or MAML or in the presence of the SEL120-34A CDK8 inhibitor is consistent with a loss of post-translational modifications ([Figure 3H](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2D,E](#fig3s2){ref-type="fig"}). Lastly, we found that treatment of protein extracts with Calf intestinal phosphatase (CIP) can abolish the mobility shift of NICD in wild type mK4 cells ([@bib74]) and to a lesser extent in SEL120-34A treated cells, whereas NICD in MAML knockout cells shows no change in mobility due to CIP treatment ([Figure 3---figure supplement 2F](#fig3s2){ref-type="fig"}). Altogether, these data indicate that Cdk8-mediated regulation of NICD degradation requires NCM complex formation on DNA in both mammalian cells and fly tissues but does not require active transcription.

Quantitative analysis of enhancer binding site induced Notch turnover {#s2-3}
---------------------------------------------------------------------

Our data support a model whereby NCM binding to *SPS-GBE* sites promotes NICD phosphorylation and degradation, and thereby reduces NICD levels in the nucleus ([Figure 4A](#fig4){ref-type="fig"}). To obtain a quantitative understanding of how changes in SPS number affect Notch signal strength, we used mathematical modeling and quantitative expression analysis. The model includes a set of biochemical reactions that describe NICD dynamics in the nucleus (bottom, [Figure 4A](#fig4){ref-type="fig"}). We initially assume unphosphorylated, unbound NICD ($NICD_{up,ub}$) enters the nucleus at a constant production rate ($P_{NICD}$), where it forms NCM complexes that bind DNA. Bound, unphosphorylated NICD ($NICD_{up,b}$) can be phosphorylated by Cdk8 ($NICD_{p,b}$) at a rate $k_{p}$, assuming that NICD is not dephosphorylated by a phosphatase. Similar to the unphosphorylated state, phosphorylated NICD can cycle between $NICD_{p,b}$ and $NICD_{p,ub}.$ Finally, it is assumed that the degradation rate of $NICD_{p,ub}$, denoted by $\Gamma_{p}$, is much faster than the degradation rate of $NICD_{up,ub}$, denoted by $\Gamma_{up}$.

![A mathematical model coupling NICD degradation to DNA binding predicts Notch activity and tissue sensitivity.\
(**A**) Schematic and equation describing *SPS-GBE* induced turnover of NICD. In both wild type (left) and nuclei with SPS-GBE sites inserted (right), NICD is produced and enters the nucleus at a constant rate ($P_{NICD}$). NCM complexes form on SPS, where NICD is phosphorylated by Cdk8 at a rate $k_{p}$. Phosphorylated NICD degrades faster ($\Gamma_{p}$) than unphosphorylated NICD ($\Gamma_{up}$). Subscripts $p,up,b,ub$ denote phosphorylated, unphosphorylated, bound, and unbound NICD. (**B**) Simulations of NICD levels as a function of SPS number. The three curves correspond to simulations with indicated values of $k_{p}$. NICD starts from a common level ($NICD_{0}$) and initially decreases linearly with SPS number, with a slope proportional to $k_{p}$. (**C**) Wing notching penetrance and severity in flies with indicated genotypes. Proportional odds model was used to assess significance. (**D--G"**) Wing discs from flies containing *6xSPS-GFP* (*6S-GFP*) and either *GBE-lacZ* (*G-lacZ*) or *(G6S)~1,2\ or\ 3-~lacZ* stained with cut (magenta). (**H**) Quantified GFP levels in wing discs with increasing SPSs (0, 6, 12, 18 correspond to *(G6S)~1,2\ or\ 3~-lacZ*) in either wild type (blue) or *skd* heterozygotes (red). Each dot represents the average GFP level in margin cells from a single wing disc. Error bars show means and S.E.M for each disc. Solid lines represent linear fit to mean GFP values of the first three points of *wild-type* (blue) and the four points of *skd* heterozygotes (red). Ratio of slopes is indicated. Effective number of endogenous SPS, $N_{e}$, is estimated by extrapolating the y axis intersect of dashed lines. (**I**) Estimated phosphorylation rates by a single SPS, $k_{p}$. Values of $k_{p}$ (color-bar) were estimated for a range of values of $NICD_{0}$ and $\Gamma_{up}$. Dashed line represents lower limit of the physiological range of kinase activities. (**J**) Quantified number of gained/lost macrochaetae from indicated genotypes in *N^55e11/+^* (blue bars) or *H^1/+^* (red bars) background. Proportional odds model with Bonferroni adjustment. Data are mean ±95% confidence interval. (**K**) NICD level simulations as a function of time after Notch activation (at t = 0 min) in *wild-type* (blue), *N* heterozygotes (yellow) and *SPS-GBE* flies (red). In tissues with long duration Notch activation (black dash line), *N* heterozygotes and *SPS-GBE* sites similarly reduce NICD levels. In tissues with short duration Notch activation (red dash line), NICD levels are weakly affected by SPS-GBE compared to *N* heterozygotes (arrows).](elife-53659-fig4){#fig4}

To test these predictions, we measured Notch signal strength in wing margin cells in the presence and absence of *SPS-GBE* transgenes. To systematically vary SPS numbers, we created fly lines containing one, two or three (*3xGBE-6xSPS*) cassettes in front of a single *lacZ* gene ((*G6S*)*n-lacZ*). Analysis of flies carrying a single copy of the (*G6S*)*n-lacZ* transgenes revealed enhanced penetrance and severity of wing notching as the number of *G6S* cassettes increased, and all were significantly suppressed by removing one *skd* allele ([Figure 4C](#fig4){ref-type="fig"}). Because direct measurement of nuclear NICD levels in vivo is very challenging ([@bib12]), we monitored NICD levels in wing margin cells indirectly via GFP expression from an independent *6xSPS-GFP* (*6S-GFP*) reporter that is highly sensitive to changes in *Notch* gene dose ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We found that GFP levels decreased as a function of added *GBE-SPS* sites ([Figure 4D--H](#fig4){ref-type="fig"}). Simultaneous analysis of Cut, an endogenous *Notch* target required for maintaining wing margin fate ([@bib51]; [@bib57]), revealed a loss of wing margin fate in a subset of (G6S)~2~-lacZ and (G6S)*~3~-lacZ* cells (arrowheads in [Figure 4E--G](#fig4){ref-type="fig"}), consistent with the notched wing phenotype observed in these animals.

Analysis of the differential equations corresponding to these reactions generated several predictions. First, our model predicts steady state NICD levels will initially decrease linearly as the number of SPSs increases and then saturate for high numbers of SPSs ([Figure 4B](#fig4){ref-type="fig"}). Importantly, the linear regime of the slope describing NICD degradation is expected to be proportional to the Cdk8 phosphorylation rate, $k_{p}$. Accordingly, if there is no dosage compensation in CKM heterozygotes, the model's second prediction is that the slope of the wild-type curve should be twice that of the heterozygous mutant curve.

Analysis of *6S-GFP* expression revealed an approximately linear decrease in GFP as the number of *G6S* cassettes is increased ([Figure 4H](#fig4){ref-type="fig"}, blue markers). Moreover, removing an allele of *skd* significantly increased *6S-GFP* expression, resulting in a shallower slope relative to wild type flies with the same (*G6S*)*-lacZ* transgene ([Figure 4H](#fig4){ref-type="fig"}, red markers). The ratio between slopes as calculated by linear regression analysis of GFP levels in wild type and *skd* heterozygotes (solid lines in [Figure 4A](#fig4){ref-type="fig"}) was 1.88 ± 0.29, in agreement with the predicted 2-fold change in the absence of CKM dosage compensation. Interestingly, the two curves did not intersect at the y-axis, reflecting a cumulative reduction in NICD phosphorylation and degradation rates at endogenous sites; an interpretation supported by the observation that CKM heterozygotes ameliorate *Notch* heterozygote induced wing notching phenotypes ([Figure 3B](#fig3){ref-type="fig"}). We used this observation to estimate the magnitude of the cumulative genomic effect by extrapolating the crossing point of the two curves (dashed lines in [Figure 4H](#fig4){ref-type="fig"}). The lines crossed at negative $N_{e} = 5.4 \pm 4.7$*SPS-GBE* sites. This value means that the cumulative effect on NICD stability of all sites in the genome (*N~e~*) is equal to that of \~5 highly active synthetic *SPS-GBE* sites.

Next, we used the model to calculate Cdk8 phosphorylation rates, $k_{p}$, needed at *SPS-GBE* sites to lower NICD concentrations and induce wing notching phenotypes. In the linear regime, $k_{p}$ (in 1/min units) can be calculated from the measured slope, $Slope_{wt}$, for different values of $NICD_{0}$, $\Gamma_{up}$, and $\Gamma_{p}$ (see [Figure 4B](#fig4){ref-type="fig"} and Materials and methods for derivation). We used a plausible range of NICD concentrations, $NICD_{0}$, (between 10^2^-10^4^ molecules per nucleus) and degradation rates $\Gamma_{up}$ (between $\frac{1}{30}{min}^{- 1} - \frac{1}{1000}{min}^{- 1}$, see Materials and methods for parameter estimation). This analysis provided a range for likely Cdk8 catalytic activity on *SPS-GBE* sites between $10^{- 1}to10^{3}{min}^{- 1}$, a large portion of which falls within the physiological regime of known kinase activities (above the dashed line in Figure 4I; [@bib13]; [@bib26]; [@bib38]). In fact, the calculated $k_{p}$ values are at the low end of the physiological range (of the order of \~1/min), suggesting that even modest phosphorylation rates could produce the observed reduction in Notch signal strength, and ultimately, wing notching phenotypes induced by *SPS-GBE* sites.

Altered NICD degradation sensitizes tissues requiring long duration signals {#s2-4}
---------------------------------------------------------------------------

Molecularly, *Notch* haploinsufficiency is due to decreased NICD production, whereas our data support the model that the phenotype caused by *SPS-GBE* sites is due to enhanced NICD turnover. This difference in mechanism might explain why *SPS-GBE* sites fail to impact another known *N* dose sensitive tissue, the macrochaetae sensory bristles ([Figure 2K--L](#fig2){ref-type="fig"}). These data support the idea that wing margin cells are sensitive to changes in both NICD production and degradation, whereas macrochaetae formation is preferentially sensitive to changes in NICD production. To further test this hypothesis, we analyzed macrochaetae formation in compound heterozygotes for CKM genes and *Notch* or *Hairless*. In contrast to the observed suppression of wing notching ([Figure 3B](#fig3){ref-type="fig"}), we found that removing an allele of each CKM gene did not significantly suppress the *Notch* haploinsufficiency of extra macrochaetae ([Figure 4J](#fig4){ref-type="fig"}). In fact, macrochaetae numbers further increased in *N;cdk8* and *N;skd* compound heterozygotes, which is opposite of the predicted outcome if slowing NICD degradation significantly elevated NICD levels during macrochaetae formation ([Figure 4J](#fig4){ref-type="fig"}). As a second test to determine if changes in the CKM could alter macrochaetae, we analyzed *H* heterozygotes that generate too few macrochaetae due to increased Notch activity ([@bib54]; [@bib48]). In this genetic background, removing an allele of either *skd* or *cdk8* did not significantly alter macrochaetae formation ([Figure 4J](#fig4){ref-type="fig"}). However, we did find that removing an allele of *cycC* had a small, but significant impact on macrochaetae formation in *H;cycC* compound heterozygotes. Given that removing a *cycC* allele did not significantly impact macrochaetae formation in *N^55e11/+^* heterozygotes, it is possible that the decrease in macrochaetae numbers in *H;cycC* compound heterozygotes is due to changes in factors unrelated to the Notch pathway. Nevertheless, these data suggest that the Notch haploinsufficient phenotypes in macrochaetae lateral inhibition and wing margin formation are differently affected by decreasing CKM levels.

A potential explanation for the tissue-specific response to *SPS-GBE* sites and CKM heterozygotes could be the distinct temporal requirements for Notch activation in each tissue. Maintenance of wing margin identity is a continuous process at least 48 hours long ([@bib15]; [@bib68]), whereas macrochaetae formation requires Notch input over a short time period (\< 30 min) ([@bib5]). To explore the relationship between Notch signal duration and sensitivity to changes in NICD production/degradation rates, we modeled the dynamics of NICD accumulation as a function of time in wild-type, *N* heterozygotes, and flies homozygous for *G6S-lacZ* ([Figure 4K](#fig4){ref-type="fig"}). We assume that *N* heterozygotes lower NICD production ($P_{NICD}$) by one half without impacting NICD degradation, whereas *SPS-GBE* sites do not affect $P_{NICD}$ but increase NICD degradation as a function of SPS number. In a scenario where nuclear NICD reaches steady state ([Figure 4K](#fig4){ref-type="fig"}, black dash line), both the *SPS-GBE* loci and *N* heterozygotes significantly decrease NICD levels. In contrast, if Notch signals are only required for a short time period, changes in degradation rates do not significantly alter NICD levels relative to the impact of losing a *N* allele ([Figure 4K](#fig4){ref-type="fig"}, arrows). We note that this conclusion is robust over a broad range of potential NICD production and degradation rates ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Moreover, the model is consistent with the results observed using genetic changes in CKM gene dose -- altering NICD degradation selectively impacts long duration events (wing margin) and not short duration events (lateral inhibition during macrochaetae specification).

Defining enhancer TF binding sites (TFBSs) that induce the notched wing phenotype {#s2-5}
---------------------------------------------------------------------------------

The synthetic Notch binding sites used in the GBE-SPS transgene were designed to minimize the inclusion of sequences bound by other known TFs (see Materials and methods). To test if an endogenous SPS sequence could induce wing phenotypes, we selected a previously characterized *E(spl)m8* SPS sequence ([@bib22]; [@bib2]; [@bib42]). The *E(spl)m8* SPS is flanked by adjacent N-box sites bound by E(spl)/Hes factors ([@bib41]), which thereby provide negative feedback downstream of Notch signaling ([Figure 5A](#fig5){ref-type="fig"}). Comparative analysis of flies carrying two copies of the synthetic *G6S(syn)-lacZ* versus the *G6Sm8-lacZ* revealed a highly similar penetrance and severity of wing notching phenotypes ([Figure 5B](#fig5){ref-type="fig"}). Thus, an endogenous SPS sequence from a known Notch-regulated enhancer can promote NICD degradation to induce a wing notching phenotype in the GBE-SPS transgene assay, even in the presence of potential negative feedback.

![Defining enhancer TFBSs that induce the notched wing phenotype.\
(**A**) Graphical representation and sequence alignment of the synthetic SPS (SPS(syn)) and E(spl)m8 SPS constructs. SPS sites are highlighted in blue and Nbox sequences, which are only present in E(spl)m8, are shaded in gray. (**B**) Quantified wing notching in flies with two copies of either *G6Ssyn-lacZ* or *G6Sm8-lacZ* inserted in the same locus. (**C**) Quantified wing notching in flies with two copies of either *5xZelda(Zld)-lacZ*, *5xZld-6xSPS-lacZ*, or *5xZld-12xCSL-lacZ*. Two-sided Fisher's exact test assessed for significance between genotypes. (**D**) Quantified wing notching in flies with two copies of either *5xEbox-lacZ* sites alone, *5xEbox-6xSPS-lacZ*, or *5xEbox-12xCSL-lacZ*. (**E**) Quantified wing notching in *N* heterozygous flies containing a single copy of either *0xSPS-lacZ* or *6xSPS-lacZ* transgenes. Proportional odds model tested for penetrance/severity.](elife-53659-fig5){#fig5}

Next, we tested if additional TFs besides Grh can synergize with SPS sites to induce phenotypes by replacing the GBE sites with either Zelda (Zld) sites or an E-box sequence that binds basic-Helix-Loop-Helix (bHLH) TFs such as the *Drosophila* E-protein Daughterless (Da). Like Grh, Zld is a pioneer factor that opens chromatin ([@bib49]), whereas the widely expressed Da E-protein has not been shown to have pioneering activity. Accordingly, we found that flies containing two copies of *5xZld-6xSPS-lacZ* induced notched wings, whereas flies with *5xZld-lacZ* or *5xZld-12xCSL-lacZ* failed to induce wing notching ([Figure 5C](#fig5){ref-type="fig"}). In contrast, 5xEbox sites failed to induce wing phenotypes when coupled to either SPS or CSL sites ([Figure 5D](#fig5){ref-type="fig"}). Taken together, these findings suggest that TFs with pioneering activity synergize with the SPS Notch dimer sites, but not the CSL Notch monomer sites, to promote Notch degradation.

The finding that pioneer TF sites are necessary to induce SPS-dependent wing phenotypes in wild type flies could be due to pioneer TFs either being strictly required to promote NICD turnover or pioneer TFs could accelerate this activity, perhaps by increasing genome accessibility. To distinguish between these possibilities, we tested if SPS enhancers lacking pioneer TF sites are capable of promoting Notch-dependent wing nicking in a sensitized genetic background. Importantly, we found that *Notch* heterozygous flies carrying a single copy of the *6S-lacZ* transgene had significantly enhanced wing notching compared to *Notch* heterozygous flies with an enhancer-less *lacZ* transgene (*0S-lacZ*) ([Figure 5E](#fig5){ref-type="fig"}). Taken together with the finding that *G6S-lacZ* and *5xZld-6S-lacZ* were sufficient to induce notched wings in wild type flies ([Figure 1K](#fig1){ref-type="fig"} and [Figure 5C](#fig5){ref-type="fig"}) whereas *6S-lacZ* failed to do so ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), these data suggest that enhancers with only SPS sites can promote NICD degradation, but to a lesser degree than those near a bound pioneer TF.

Discussion {#s3}
==========

Our results show that simply increasing the number of clustered Notch dimer sites (SPS) linked to sites for a pioneer TF can cause a tissue-specific *N* haploinsufficiency phenotype via a Cdk8-dependent mechanism. These findings have important implications for both enhancer biology and the mechanisms regulating Notch signal strength in specific tissues. First, the proposed Cdk8-dependent mechanism links the rapid degradation of the Notch signal (NICD) with its binding to specific loci (SPSs) in a manner that can be uncoupled from transcription activation. This 'bind and discard' mechanism reveals an unexpected global link between accessible binding sites in the epigenome, such that the collective 'drain' loci can reduce Notch-dependent transcription at other loci in the same nucleus. Moreover, since the binding sites do not have to be coupled with transcription to induce a notched wing phenotype, our findings highlight the possibility that seemingly non-functional genomic binding events could impact TF metabolism in a Cdk8-dependent manner. Given that Cdk8 interacts with many genomic loci ([@bib62]) and that a previous phospho-proteomic study identified numerous transcriptional regulators are targets of CDK8/19 phosphorylation ([@bib65]), such a mechanism may be quite general and apply to transcription regulators beyond Notch.

While our genetic and cell culture data, as well as previous phosphorylation studies, support a direct link between CKM activity and NICD degradation ([@bib21]), it should be noted that the CKM also phosphorylates other proteins that could contribute to the differences in wing versus macrochaetae phenotypes ([@bib65]). Intriguingly, one of the high confidence CKM targets in mammalian cells was MAML1, indicating that CKM activity may directly regulate Notch output by phosphorylating multiple components of the Notch transcription complex. In addition, CCNC (CycC), MED12, and MED13 were all found to be high confidence CDK8/19 targets ([@bib65]), suggesting that CKM activity may directly impact the turnover of key components of its own complex. It's thus not surprising that removing an allele of *cycC*, *kto* (*med12)* or *skd* (*med13)* had a much larger impact on the *Notch* haploinsufficient wing phenotype compared to changing the gene dose of *cdk8*. Moreover, these genetic data are consistent with prior studies in yeast showing that structural/regulatory components of macromolecular complexes, such as CycC/Med12/Med13, are enriched in haploinsufficiency genes, whereas enzymes are generally under-represented from the list of dose sensitive genes ([@bib39]).

Second, our data support the idea that not all Notch binding sites are equally capable of marking NICD for degradation, and that enhancer architecture plays a key role in modulating NICD turnover. For instance, only Notch dimer but not Notch monomer sites are sufficient to generate phenotypes, and even SPS-containing enhancers differ in their ability to induce phenotypes based on the absence/presence of pioneer TF sites. Notably, we found that enhancers with either synthetic SPS sites designed to limit additional TF input or an endogenous *E(spl)m8* SPS with adjacent binding sites capable of providing negative feedback were sufficient to induce notched wing phenotypes when coupled to pioneer TF sites. Since Grh and Zld binding is sufficient to increase chromatin opening ([@bib49]; [@bib34]), these findings suggest enhancer accessibility alters the rate at which NICD is metabolized by Notch dimer sites. Intriguingly, ChIP-seq data for Grh ([@bib58]) and Zld ([@bib28]) reveals extensive binding to the *Enhancer of Split* (*E(spl)*) locus that contains numerous SPS-containing *Notch* regulated enhancers ([@bib9]; [@bib11]; [@bib56]). However, it is important to note that while an SPS-containing enhancer lacking pioneer TF sites failed to induce phenotypes in wild type flies, it did significantly increase wing notching in a sensitized genetic background. These findings suggest that SPS-containing enhancers promote NICD degradation at differing rates based on the presence of nearby TF sites. While the mechanistic basis for how SPS but not CSL sites promote NICD degradation is not known, these data highlight a potential mechanism by which enhancer architecture (i.e. Notch dimer vs monomer sites) and epigenetic 'context' (i.e. accessibility due to pioneer TF binding) can fine tune the global Notch response in different tissues.

The finding that introducing as few as 12 SPS sites into the genome can induce notched wing phenotypes raises the question of how many functional SPS sites exist in the endogenous genome. Recent studies found that about one third of direct *Notch* target genes (38 of 107 genes) in human T-ALL are regulated by SPS sites ([@bib67]), and a mouse mK4 cell line has an estimated 2500 Notch dimer dependent binding sites ([@bib29]). These findings suggest that many SPS sites are accessible across the mammalian genome. The estimated number of SPS sites within the *Drosophila* genome, which is an order of magnitude smaller than most mammalian genomes, remains to be determined. However, of the 154 Notch-responsive genes identified in a *Drosophila* wing disc-derived cell line, eight encode *E(spl)* genes that are clustered within a common 40 kb locus and many *E(spl)* genes contain one or more SPS sites ([@bib30]). In comparison to the *E(spl)* locus, the 6 SPS sites within the *G6S-lacZ* transgene are found within \~300 bps, and thus it is possible that concentrating SPS sites might provide an avidity impact that increases the probability of a recruited NICD molecule being marked for degradation. In fact, we estimated that the cumulative effect of the *Drosophila* genome is equal to \~5 highly accessible, linked *SPS-GBE* sites. Future studies using endogenous SPS-containing enhancers will be needed to provide a better understanding of both the role of nearby binding sites for other TFs and how concentrating SPS sites in specific loci impacts the wing notching phenotype.

Third, we propose that the differential sensitivity of Notch-dependent tissues to changes in NICD degradation (i.e. *SPS-GBE* sites or CKM heterozygotes) or production rates (*N* heterozygotes) reflects the temporal requirement for Notch signal duration. An appealing aspect of this Notch signal duration model is that it predicts that any perturbation that alters NICD signal degradation will preferentially affect long-duration processes over short duration processes, whereas perturbations that impact NICD signal production will affect both long and short duration events. Moreover, the differential sensitivity of the Notch duration model to changes in production versus degradation rates may be generalizable to the study of other signaling pathways. However, it's worth noting that additional differences between the wing and macrochaetae besides signal duration may contribute to the magnitude of change in Notch signal strength in each tissue. As an example, *cis*-inhibition, which determines the fraction of functional Notch receptors on the cell membrane ([@bib43]; [@bib63]; [@bib80]), could play a cell-specific role in modulating NICD production to a larger degree in one tissue over another. Taking this mechanism into consideration, the assumption that *Notch* heterozygotes reduce NICD production by 50 percent in each tissue may be over-simplified. Thus, further experiments using a system that is amenable to systematic changes in the length of Notch signal induction are needed to thoroughly test the signal duration model in multiple tissues.

Intuitively, the duration model suggests a mechanism underlying cell-specific context that may have implications for both developmental processes and tumorigenesis. For example, mutations in the NICD PEST domain that decouple DNA binding and degradation are common in T-ALL ([@bib76]), and CycC (*CCNC*) functions as a haploinsufficient tumor suppressor gene in T-ALL, at least in part, by stabilizing NICD ([@bib45]). These findings suggest that T-ALL is highly sensitive to alterations in NICD degradation. Indeed, T-ALL cells are 'addicted' to Notch and are thus dependent on a long duration signal ([@bib67]). As \~30% of Notch target genes in T-ALL use SPS containing enhancers, our findings provide insight into how Notch PEST truncations and *CCNC* heterozygotes could each promote tumorigenesis by slowing CKM-mediated NICD turnover on SPS enhancers. Future studies focused on enhancers that recruit the CKM and other Notch-dependent cellular processes will help reveal how the temporal requirements for nuclear activities contributes to both normal development and disease states.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                         Designation                                                 Source or reference                                             Identifiers                                                                     Additional\
  (species) or resource                                                                                                                                                                                                                             information
  ------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Genetic reagent (*D. melanogaster*)   BAC{Notch}                                                  Bloomington*Drosophila* Stock Center                            BDSC:38665; RRID:[BDSC_81271](https://scicrunch.org/resolver/BDSC_81271)        FlyBase symbol: PBac{N-GFP.FLAG}VK00033

  Genetic reagent (*D. melanogaster*)   N\[55e11\]                                                  Bloomington*Drosophila* Stock Center                            BDSC:28813; RRID:[BDSC_28813](https://scicrunch.org/resolver/BDSC_28813)        

  Genetic reagent (*D. melanogaster*)   H\[1\]                                                      Bloomington*Drosophila* Stock Center                            BDSC:515; RRID:[BDSC_515](https://scicrunch.org/resolver/BDSC_515)              

  Genetic reagent (*D. melanogaster*)   kto\[T241\]                                                 Bloomington*Drosophila* Stock Center                            BDSC:63126; RRID:[BDSC_63126](https://scicrunch.org/resolver/BDSC_63126)        

  Genetic reagent (*D. melanogaster*)   kto\[T631\]                                                 Bloomington*Drosophila* Stock Center                            BDSC:63125; RRID:[BDSC_63125](https://scicrunch.org/resolver/BDSC_63125)        

  Genetic reagent (*D. melanogaster*)   skd\[T13\]                                                  Bloomington*Drosophila* Stock Center                            BDSC:63123; RRID:[BDSC_63123](https://scicrunch.org/resolver/BDSC_63123)        

  Genetic reagent (*D. melanogaster*)   skd\[T413\]                                                 Bloomington*Drosophila* Stock Center                            BDSC:63124; RRID:[BDSC_63124](https://scicrunch.org/resolver/BDSC_63124)        

  Genetic reagent (*D. melanogaster*)   cdk8\[K185\]                                                PMID:[11171343](https://www.ncbi.nlm.nih.gov/pubmed/11171343)                                                                                   

  Genetic reagent (*D. melanogaster*)   cycC\[Y5\]                                                  PMID:[11171343](https://www.ncbi.nlm.nih.gov/pubmed/11171343)                                                                                   

  Genetic reagent (*D. melanogaster*)   ago\[1\]                                                    PMID:[11565033](https://www.ncbi.nlm.nih.gov/pubmed/11565033)                                                                                   

  Genetic reagent (*D. melanogaster*)   ago\[3\]                                                    PMID:[11565033](https://www.ncbi.nlm.nih.gov/pubmed/11565033)                                                                                   

  Cell line (*H. sapiens*)              HEK293T                                                     PMID:[23806616](https://www.ncbi.nlm.nih.gov/pubmed/23806616)                                                                                   Stable expression of CLuc-RBPjK and Notch1-NLuc

  Cell line (*M. musculus*)             mK4                                                         PMID:[11850199](https://www.ncbi.nlm.nih.gov/pubmed/11850199)   RRID:[CVCL_9T80](https://scicrunch.org/resolver/CVCL_9T80)                      

  Cell line (*M. musculus*)             OT-13                                                       PMID:[9374409](https://www.ncbi.nlm.nih.gov/pubmed/9374409)     RRID:[CVCL_T371](https://scicrunch.org/resolver/CVCL_T371)                      wild-type embryonic fibroblast

  Cell line (*M. musculus*)             OT-11                                                       PMID:[9374409](https://www.ncbi.nlm.nih.gov/pubmed/9374409)     RRID:[CVCL_T370](https://scicrunch.org/resolver/CVCL_T370)                      RBPjK deficient embryonic fibroblast

  Antibody                              anti-NICD Cleaved Notch1 Val1744 D3B8 (Rabbit monoclonal)   CST                                                             Cat \# 4147; RRID:[AB_2153348](https://scicrunch.org/resolver/AB_2153348)       WB (1:1000)

  Antibody                              anti-Notch1 Clone D1E11 (Rabbit monoclonal)                 CST                                                             Cat\# 3608; RRID:[AB_2153354](https://scicrunch.org/resolver/AB_2153354)        WB (1:1000)

  Antibody                              anti-cut (Mouse monoclonal)                                 DSHB                                                            Cat\# 2B10                                                                      IF (1:50)

  Antibody                              anti-β-Actin Clone AC-15 (Mouse monoclonal)                 Sigma-Aldrich                                                   Cat\# A5441; RRID:[AB_476744](https://scicrunch.org/resolver/AB_476744)         WB (1:4000)

  Antibody                              anti- MAML1 D3E9 (Rabbit monoclonal)                        CST                                                             Cat\# 11959; RRID:[AB_2797778](https://scicrunch.org/resolver/AB_2797778)       WB (1:1000)

  Antibody                              anti-MAML2 (Rabbit polyclonal)                              CST                                                             Cat\# 4618; RRID:[AB_2139273](https://scicrunch.org/resolver/AB_2139273)        WB (1:1000)

  Antibody                              anti-MAML3 (Rabbit polyclonal)                              Bethyl                                                          Cat\# A300-684A; RRID:[AB_2266032](https://scicrunch.org/resolver/AB_2266032)   WB (1:1000)

  Antibody                              anti-RUNX1 D4A6 (Rabbit monoclonal)                         CST                                                             Cat\# 8529; RRID:[AB_10950225](https://scicrunch.org/resolver/AB_10950225)      WB (1:1000)

  Antibody                              ECL anti-rabbit-HRP                                         GE Healthcare                                                   Cat\# NA934; RRID:[AB_772206](https://scicrunch.org/resolver/AB_772206)         WB (1:5000)

  Antibody                              ECL anti-mouse-HRP                                          GE Healthcare                                                   Cat\# NA931; RRID:[AB_772210](https://scicrunch.org/resolver/AB_772210)         WB (1:5000)

  Sequence-based reagent                MAML1 exon1 PX458 F                                         This paper                                                      guide RNA                                                                       CACCGCCGAAGTGGCAGCCGGCGCC

  Sequence-based reagent                MAML1 exon1 PX458 R                                         This paper                                                      guide RNA                                                                       AAACGGCGCCGGCTGCCACTTCGGC

  Sequence-based reagent                MAML1 exon1 PX459 F                                         This paper                                                      guide RNA                                                                       CACCGCGCCGGAAGAGGCGTTTTC

  Sequence-based reagent                MAML1 exon1 PX459 R                                         This paper                                                      guide RNA                                                                       AAACGAAAACGCCTCTTCCGGCGC

  Sequence-based reagent                MAML2 exon1 PX458 F                                         This paper                                                      guide RNA                                                                       CACCGGGGGCCTCCCAGTAAATAA

  Sequence-based reagent                MAML2 exon1 PX458 R                                         This paper                                                      guide RNA                                                                       AAACTTATTTACTGGGAGGCCCCC

  Sequence-based reagent                MAML2 exon1 PX459 F                                         This paper                                                      guide RNA                                                                       CACCGACTCCCACCAGTGATTAGTT

  Sequence-based reagent                MAML2 exon1 PX459 R                                         This paper                                                      guide RNA                                                                       AAACAACTAATCACTGGTGGGAGTC

  Sequence-based reagent                MAML3 exon1 PX458 F                                         This paper                                                      guide RNA                                                                       CACCGCTCCCGGGGCACACTATTT

  Sequence-based reagent                MAML3 exon1 PX458 R                                         This paper                                                      guide RNA                                                                       AAACAAATAGTGTGCCCCGGGAGC

  Sequence-based reagent                MAML3 exon1 PX459 F                                         This paper                                                      guide RNA                                                                       CACCGCTCACTGGGGTGCGCGTTG

  Sequence-based reagent                MAML3 exon1 PX459 R                                         This paper                                                      guide RNA                                                                       AAACCAACGCGCACCCCAGTGAGC

  Chemical compound, drug               Actinomycin D                                               Sigma-Aldrich                                                   Cat\# A1410                                                                     

  Chemical compound, drug               Senexin A                                                   R and D                                                         Cat\# 4875                                                                      

  Chemical compound, drug               SEL120-34A                                                  Medchemexpress                                                  Cat\# HY-111388A                                                                

  Chemical compound, drug               CIP                                                         NEB                                                             Cat\# M0525S                                                                    

  Chemical compound, drug               D-Luciferin                                                 Goldbio                                                         Cat\# LUCK-100                                                                  

  Chemical compound, drug               Trypsin-EDTA                                                Gibco                                                           Cat\# 25300--120                                                                

  Chemical compound, drug               SuperSignalFemto West Chemoluminescent Substrate            Thermo-Fisher Scientific                                        Cat\# PI34095                                                                   

  Software, algorithm                   MATLAB                                                      Mathworks                                                       RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)                    Codes available at <https://github.com/OhadGolan/NICD-concentration-in-the-nucleus-as-by-binding-site-coupled-NICD-degradation>
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reporter design, molecular cloning, and transgenic fly generation {#s4-1}
-----------------------------------------------------------------

All synthetic Notch enhancer sequences contain high affinity Su(H) binding sites (CGTGGGAA). Notch monomer sites (CSL) were placed 17bps apart in a head-to-tail manner to permit independent binding of NCM complexes. Notch dimer sites (SPS) were spaced 15bps apart in a head-to-head orientation to enable cooperative dimerization between adjacent NCM complexes. Intervening sequences were designed to exclude known binding sites for other *Drosophila* TFs using the *cisBP* website ([@bib75]). The 6xSPSmut sequence is identical to 6xSPS except for two nucleotide changes in each site in positions previously shown to disrupt CSL binding (CG[A]{.ul}GG[C]{.ul}AA) ([@bib71]). The 2xSPS, 6xSPS, 6xSPSmut, 12xCSL, 6xSPSm8, 5xZelda and 5xEbox sequences were synthesized by GenScript as either complementary oligonucleotides (2xSPS) or double stranded DNA (6xSPS, 6xSPSmut, 12xCSL, 6xSPSm8, 5xZelda, and 5xEbox; complete sequences listed below). Cloning was facilitated by including flanking EcoR1 and HindIII/BglII sequences. Annealed oligonucleotides or double stranded DNA fragments were cloned into either *placZ-attB* or *3xGBE-placZ-attB* ([@bib73]) and sequence confirmed. To concatenate 6xSPS into larger arrays, a shuttle vector was used to generate a BamH1-6xSPS-BglII-Not1 fragment for reiterative cloning into vectors digested with BglII/NotI (BglII/NotI permits cloning BamH1/NotI fragments, which can be repeated as desired). To create the *3xGBE-24xSPS-lacZ* vector, a *24xSPS* fragment (generated in the shuttle vector) was cloned into the *3xGBE-lacZ* vector. To make the promoter containing *3xGBE-24xSPS-GFP* vector, we inserted *3xGBE-24xSPS* into *pHStinger-attB* ([@bib6]). To generate a promoterless *3xGBE-24xSPS* construct, the promoter and GFP encoding sequences were removed from *3xGBE-24xSPS-GFP* by KpnI/SpeI digest, blunted with T4 DNA polymerase, and ligated. To generate the (*3xGBE-6xSPS*)*n-lacZ* (n = 2,3) constructs, the *3xGBE-6xSPS* fragment was iteratively cloned into the *3xGBE-6xSPS-lacZ* plasmid. The *6xSPS-GFP* reporter used to measure Notch transcription responses was generated by cloning 6xSPS into the *pHStinger-attB* vector. All transgenic fly lines were generated by phiC31 recombinase integration into 22A, 51C or 86Fb loci of the *Drosophila* genome (Rainbow Transgenic Flies, Inc) with the transgene insertion location for each experiment listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Synthetic enhancer DNA and probe design {#s4-2}
---------------------------------------

Enhancer sequences used in the transgenic reporter vectors and the DNA probes used in electromobility shift assays (EMSAs) are listed in FASTA format. Sequences are annotated as following: Restriction enzyme sites (RE) and/or RE overhangs (italics), Su(H) binding sites (blue), Zelda and Ebox binding sites (purple), Nbox (red) and point mutations (bold and underlined).

1.  \>6xSPS

    1.  *GAATTC*AGCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGCAGGGCAGCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGCAGGGCAGCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGCAGGGCAGCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGCAGGGCAGCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGCAGGGCAGCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGCAGGGC*AGATCT*

2.  \>6xSPS-mut

    1.  *GAATTC*AGCTACG**[A]{.ul}**GG**[C]{.ul}**AAAGGAGCAAACTGCGTTT**[G]{.ul}**CC**[T]{.ul}**CGTTCGCAGGGCAGCTACG**[A]{.ul}**GG**[C]{.ul}**AAAGGAGCAAACTGCGTTT**[G]{.ul}**CC**[T]{.ul}**CGTTCGCAGGGCAGCTACG**[A]{.ul}**GG**[C]{.ul}**AAAGGAGCAAACTGCGTTT**[G]{.ul}**CC**[T]{.ul}**CGTTCGCAGGGCAGCTACG**[A]{.ul}**GG**[C]{.ul}**AAAGGAGCAAACTGCGTTT**[G]{.ul}**CC**[T]{.ul}**CGTTCGCAGGGCAGCTACG**[A]{.ul}**GG**[C]{.ul}**AAAGGAGCAAACTGCGTTT**[G]{.ul}**CC**[T]{.ul}**CGTTCGCAGGGCAGCTACG**[A]{.ul}**GG**[C]{.ul}**AAAGGAGCAAACTGCGTTT**[G]{.ul}**CC**[T]{.ul}**CGTTCGCAGGGC*AGATCT*

3.  \>12xCSL

    1.  *GAATTC*GCCCTGCGAACGTGGGAAACCTAGGCTAGAGGCACCGTGGGAAACTGCCTGCCCTGCGAACGTGGGAAACCTAGGCTAGAGGCACCGTGGGAAACTGCCTGCCCTGCGAACGTGGGAAACCTAGGCTAGAGGCACCGTGGGAAACTGCCTGCCCTGCGAACGTGGGAAACCTAGGCTAGAGGCACCGTGGGAAACTGCCTGCCCTGCGAACGTGGGAAACCTAGGCTAGAGGCACCGTGGGAAACTGCCTGCCCTGCGAACGTGGGAAACCTAGGCTAGAGGCACCGTGGGAAACTGCCT*AGATCT*

4.  \>2xSPS_Cloning_oligonucletide\#1

    1.  *aattc*AGCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGCAGGGCAGCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGCAGGGC*a*

5.  \>2xSPS_Cloning_oligonucleotide\#2

    1.  *gatct*GCCCTGCGAACGTGGGAAACGCAGTTTGCTCCTTTCCCACGTAGCTGCCCTGCGAACGTGGGAAACGCAGTTTGCTCCTTTCCCACGTAGCT*g*

6.  \>5xZelda

    1.  *AAGCTT*TGCAGGTAGACGCAGTTTGCTCCTGCAGGTAGTAGCTGCCCTGCGATGCAGGTAGACGCAGTTTGCTCCTGCAGGTAGTAGCTGCCCTGCGATGCAGGTAG*GAATTC*

7.  \>5xEbox

    1.  *AAGCTT*GCCAGGTGTACGCAGTTTGCTCCTGCCAGGTGTTAGCTGCCTGCGAAGCCAGGTGTACGCAGTTTGCTCCTGCCAGGTGTTAGCTGCCTGCGAAGCCAGGTGT*GAATTC*

8.  \>6xSPSm8

    1.  *GAATTC*AGCTTGTGTGAGAAACTTACTTTCAGCTCGGTTCCCACGCCACGAGCCACAAGTTGTGTGAGAAACTTACTTTCAGCTCGGTTCCCACGCCACGAGCCACAAGTTGTGTGAGAAACTTACTTTCAGCTCGGTTCCCACGCCACGAGCCACAAGTTGTGTGAGAAACTTACTTTCAGCTCGGTTCCCACGCCACGAGCCACAAGTTGTGTGAGAAACTTACTTTCAGCTCGGTTCCCACGCCACGAGCCACAAGTTGTGTGAGAAACTTACTTTCAGCTCGGTTCCCACGCCACGAGCCACAAG*AGATCT*

9.  \>1xSPS_EMSA_oligonucleotide

    1.  GCTACGTGGGAAAGGAGCAAACTGCGTTTCCCACGTTCGTAGTGCGGGCGTGGCT

10. \>2xCSL_EMSA_oligonucleotide

    1.  CGAACGTGGGAAACCTAGGCTAGAGGCACCGTGGGAAACTAGTGCGGGCGTGGCT

11. \>EMSA_5'IRDye-700/800_complementary_oligonucleotide

    1.  AGCCACGCCCGCACT

Fly husbandry {#s4-3}
-------------

The following alleles were obtained from the Bloomington *Drosophila* Stock Center: PBac{N-GFP.FLAG}VK00033 (stock \#38665), N\[55e11\] (\#28813), H\[1\] (\#515), kto\[T241\] (\#63126), kto\[T631\] (\#63125), skd\[T13\] (\#63123) and skd\[T413\] (\#63124). cdk8\[K185\] and cycC\[Y5\] alleles were gifts from Professor [@bib70]. ago\[1\] and ago\[3\] alleles were previously described ([@bib52]). Flies were maintained under standard conditions with all genetic crosses, phenotyping and gene expression assays performed at 25°C. The detailed genetic crosses needed to generate the progeny in each Figure are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Genetic assays {#s4-4}
--------------

To analyze the wing notching and macrochaetae phenotypes, flies of the appropriate genotypes were mated in cornmeal-containing vials and transferred to fresh food every day. During our studies, we observed that changes in food quality and overcrowding could change the severity/penetrance of wing phenotypes, introducing variation. Hence, all experiments quantifying wing phenotypes within each Figure panel contained control flies that were grown on the same batch of food and with a similar animal density. Offspring of the listed genotypes were selected and the number of nicks on each wing was recorded and/or the number of dorsocentral and scutellar macrochaetae was counted. A Fisher's exact test was used to determine significance between samples when penetrance was being assessed (i.e. no phenotype versus a phenotype), whereas a proportional odds model was used to determine significance when the analysis included phenotype severity.

For L5 wing vein length, fly wings of the proper genotypes were dissected, mounted on glass slides and imaged using a Nikon NiE upright widefield microscope. The total length of the presumptive L5 vein and the vein-missing gap were measured using Imaris software. Student's t-test was used to determine significance.

GFP reporter assays in larval imaginal wing discs {#s4-5}
-------------------------------------------------

To systematically assess Notch transcription responses in larval wing imaginal discs, animals homozygous for *6xSPS-GFP~22A~* and either *3xGBE-lacZ*, *3xGBE-6xSPS-lacZ*, *(3xGBE-6xSPS)~2~-lacZ*, or *(3xGBE-6xSPS)~3~-lacZ* were mated to either *yw* (wild type) or *skd\[T413\]/TM6B* males. Imaginal discs from male non-TM6B wandering 3^rd^ instar larvae (*skd\[T413\]* heterozygotes) were dissected and fixed in 4% formaldehyde for 15 min. Samples were subsequently washed 4 times with PBX (0.3% Triton X-100 in PBS) and incubated with an antibody that recognizes the Cut antigen (mouse 1:50, DSHB) followed by a fluorescent-conjugated secondary antibody (Alexa Fluor, Molecular Probes). For quantitative purposes, at least eight imaginal discs were analyzed for each genetic condition tested and the entire wild type imaginal disc series was harvested, fixed and imaged at the same time using a Nikon A1R inverted confocal microscope (40x objective). For the *skd* heterozygote series, a set of wild type imaginal discs with *3xGBE-lacZ* was performed simultaneously to normalize the responses between series. All imaging was performed with constant settings for GFP levels, and GFP pixel intensity in wing margin cells was determined from Z-stack images using Imaris software. Two-sided Student's t-test was used to determine significance between samples.

Protein purification and electrophoretic mobility shift assay (EMSA) {#s4-6}
--------------------------------------------------------------------

For recombinant protein purification, constructs that correspond to mouse RBPJ (aa 53--474), mouse N1ICD (aa 1744--2113), human MAML1 (aa 1--280), fly Su(H) (aa 98--523), fly NICD (aa 1763--2412) and fly Mastermind (aa 87--307) were expressed and purified from bacteria using a combination of affinity (Ni-NTA or Glutathione), ion exchange, and size exclusion chromatography as previously described ([@bib19]). Purified proteins were confirmed by SDS-PAGE with Coomassie blue staining and concentrations were measured by absorbance at UV280 with calculated extinction coefficients. EMSAs were performed as previously described using native polyacrylamide gel electrophoresis ([@bib73]; [@bib72]). Proteins concentrations for each gel are listed in figure legends. Acrylamide gels were imaged using the LICOR Odyssey CLx scanner.

Split luciferase assay and half-life estimations {#s4-7}
------------------------------------------------

Stability of mammalian N1ICD was analyzed using the previously described split-luc HEK293T cells ([@bib46]; [@bib32]; [@bib31]). These cells, which were engineered, generated and continuously maintained by the Kopan lab, express unique fusion proteins (CLuc-RBPjK and NOTCH1-NLuc) that provide a luciferase complementation assay. The cell line was authenticated by the inducible activation of Notch leading to the successful recapitulation of published data using the Luciferase complementation assay. In this study, these HEK293T cells were cultured for 8 hr with 50 nM Actinomycin D to block transcription or 4 hr in the presence of the inhibitor Senexin A to block CDK8/CDK19-mediated phosphorylation. Alternatively, cells were incubated 1 hr with 1 μM SEL120-34A (Medchemexpress) to block CDK8/19 mediated phosphorylation. Each inhibitor was present throughout the entire time-course of each respective experiment. Cells were activated for 10 min with 0.05% Trypsin-EDTA or with Trypsin only as a negative control and transferred to Poly-D-Lysine coated black 96-well plates with 40,000 cells/well. Cells were cultured at 37°C for 1 hr to let cells attach. Medium was changed to Opti-MEM (Gibco) with 50 nM ActD, 1 μM SEL120-34A or the indicated concentration of Senexin A, and 150 μg/ml of D-Luciferin (Goldbio) substrate was added fresh before each measurement. The first measurement (t = 0) was carried out 1 hr after activation. Luciferase signals were measured using the IVIS Lumina LT system and were normalized to Trypsin treated controls and each well separately to the signal counts at t = 0.

To confirm the activity of Actinomycin D, mK4 cells with a stably integrated a 6xSPS-NanoLuc reporter or a 0xSPS-NanoLuc construct as control were used. Cells were cultured for 8 hr with 50 nM Actinomycin D or 0.1% DMSO and activated for 10 min with 0.05% Trypsin-EDTA (Gibco). Nano-Luc activity was measured after 3 hr using the Nano-Glo Luciferase Assay (Promega) and imaged with the IVIS Lumina LT system.

Since the decay curves in Figure 3 did not exhibit simple exponential decay, we calculated the half-life values by fitting the luciferase activity values to a decreasing Hill function, $\frac{{t_{0.5}}^{n} + bg \bullet t^{n}}{{t_{0.5}}^{n} + t^{n}},$ where t is time, $t_{0.5}$ is the half life, $bg$ is the background level, and $n$ is the Hill coefficient. The fitting was performed using the least mean square fitting algorithm in MATLAB. The half-life values are presented with 95% confidence intervals.

Western blot analysis {#s4-8}
---------------------

Mouse Kidney 4 (mK4) cells, which were developed by and a kind gift from Steve Potter's lab ([@bib74]), were routinely authenticated by transcriptomic (RNAseq) and functional genomic (ATAC-seq) studies. For Western blot analysis of mammalian N1ICD, mK4 cells were cultured 8 hr with 50 nM Actinomycin D (Sigma-Aldrich, A1410), 1 hr with 2 μM SEL120-34A or 0.1% DMSO in medium before activation of NOTCH with 0.05% Trypsin-EDTA (Gibco) for 10 min. Cells cultured in medium containing DMSO, Actinomycin D or SEL120-34A and harvested at different timepoints (t = 0 was taken 15 min after activation), lysed in RIPA for 30 min and sonicated. For the phosphatase treatment studies, lysates were mixed with the same amount of CIP-buffer (100 mM NaCl, 50 mM Tris-HCL pH 7.9, 10 mM MgCl~2~, 1 mM DTT) and incubated with Calf intestinal phosphatase (CIP, NEB; 20,000U/1 × 10^6^ cells) for 60 min at 37°C. Equal amounts were loaded on 6% Acrylamide gels for SDS-PAGE and blotted on Nitrocellulose membranes (GE healthcare). Membranes were blocked in 5% dry milk powder in PBS with 0.1% Tween and incubated with anti-N1ICD (Val1744, CST, 1:1000), anti-Notch1 (D1E11, CST, 1:1000) and anti-β-actin (Sigma-Aldrich, 1:4000) overnight at 4°C. After incubation with HRP-conjugated secondary antibodies (GE Healthcare, 1:5000), signals were detected using SuperSignal Femto West Chemoluminescent Substrate (Thermo Fisher Scientific) and imaged with the BioRad ChemiDoc system.

Mouse embryonic fibroblast cells deficient for RBP-JK (OT-11) ([@bib35]) or wild-type control (OT-13) cells were collected at various times after trypsin/EDTA treatment from confluent wells of a 12 well plate. The OT-11 cells were authenticated by showing a lack of target gene responsiveness to Notch stimulation and via Western blot analysis showing a loss of RBPJ protein. The cells were washed with PBS, lysed in 100 μL of RIPA + protease inhibitors and 100 μL of 2X sample buffer, and DNA was sheared with a needle. Equivalent amounts of lysate were run on an SDS polyacrylamide gel, transferred to nitrocellulose, blotted for active (Val1744, CST, 1:1000) or total Notch1 protein (D1E11, CST, 1:1000), and developed as described above.

We generated mK4 cells deficient for all mastermind-like proteins through CRISPR Cas9 mediated deletion of exon 1 of Mastermind-like 1, 2, and 3. Briefly, parental mK4 cells were simultaneously transfected with PX458 and PX459 containing guide RNAs flanking exon1 for each of the Mastermind-like genes and subjected to selection with puromycin for 2 days. Surviving clones were picked and authenticated the following week using cloning disks and screened by PCR analysis and Western blot to identify clones that lacked expression of Mastermind-like 1, 2, and 3. The sequences of guide RNAs and genotyping PCR primers are in Key Resources Table. All cell lines used throughout these studies were tested negative for mycoplasma contamination and no cell lines were used from the list of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee.

Mathematical model {#s4-9}
------------------

The mathematical model describes the concentrations of the possible states of NICD. These include unphosphorylated unbound NICD, $NICD_{up,ub}$, unphosphorylated bound, $NICD_{up,b}$, phosphorylated bound, $NICD_{p,b}$, and phosphorylated unbound, $NICD_{p,ub}$. The dynamic equations described by the set of biochemical reactions presented in [Figure 4a](#fig4){ref-type="fig"} are:$$\frac{d}{dt}NICD_{up,ub} = P_{NICD} - NICD_{up,ub}\Gamma_{up} - NICD_{up,ub}N_{ub}k_{\alpha}^{+} + NICD_{up,b}k_{\alpha}^{-}$$$$\frac{d}{dt}NICD_{up,b} = NICD_{up,ub}N_{ub}k_{\alpha}^{+} - NICD_{up,b}k_{\alpha}^{-} - NICD_{up,b}k_{p}$$$$\frac{d}{dt}NICD_{p,b} = NICD_{up,b}k_{p} - NICD_{p,b}k_{\alpha}^{-} + NICD_{p,ub}N_{ub}k_{\alpha}^{+}$$$$\frac{d}{dt}NICD_{p,ub} = NICD_{p,b}k_{\alpha}^{-} - NICD_{p,ub}\Gamma_{p} - NICD_{p,ub}N_{ub}k_{\alpha}^{+}$$

Here, $P_{NICD}$ is the rate NICD enters the nucleus (production rate), $\Gamma_{p}$ and $\Gamma_{up}$ are the degradation rates of phosphorylated/unphosphorylated NICD, respectively, $k_{\alpha}^{+},k_{\alpha}^{-}$ are the association and dissociation rates of the NCM complex to an SPS site, $k_{p}$ is the Cdk8 phosphorylation rate of bound unphosphorylated NICD, and $N_{ub}$ is the number of unbound SPS sites.

The total nuclear NICD concentration, $NICD_{tot}$, is the sum of the phosphorylated, $NICD_{p}$, and unphosphorylated fractions, $NICD_{up}$:$$NICD_{tot} = NICD_{p} + NICD_{up}$$

The total phosphorylated and unphosphorylated NICD are the sum of the bound (index b) and unbound (index ub) fractions:$$NICD_{p} = NICD_{p,b} + NICD_{p,ub}$$$$NICD_{up} = NICD_{up,b} + NICD_{up,ub}$$

Combining [Equations 1,2, 3, 4, 5, 6, 7](#equ1 equ2 equ3 equ4 equ5 equ6 equ7){ref-type="disp-formula"} and assuming the system is in steady state gives:$$0 = NICD_{0} - NICD_{up} - NICD_{up,b}\left( k_{p}^{'} - 1 \right)$$$$0 = NICD_{up,b}k_{p}^{'} - NICD_{p}\Gamma_{p}^{'} + NICD_{p,b}\Gamma_{p}^{'}$$where we define the dimensionless parameters: $NICD_{0} \equiv \frac{P_{NICD}}{\Gamma_{up}}$, $\Gamma_{p}^{'} \equiv \frac{\Gamma_{p}}{\Gamma_{up}}$, $k_{p}^{'} =$$\frac{k_{p}}{\Gamma_{up}}$.

$NICD_{up,b}$ and $NICD_{p,b}$ are calculated using a physical model based on equilibrium statistical mechanics ([@bib8]). The conceptual basis of such models is that the occupancy of binding sites can be deduced by examining the equilibrium probabilities of binding and unbinding of TFs to TFBSs. In such models, each state of the system is denoted with a statistical weight ($S_{i}$). In equilibrium, the statistical weights can be represented as the ratio of the concentration of each binding species $\left\lbrack X \right\rbrack$, to the dissociation rate $k_{d}^{\lbrack X\rbrack}$ associated with that interaction so that $S_{i} = \left\lbrack X \right\rbrack/k_{d}^{\lbrack x\rbrack}$ ([@bib77]). The partition function is defined as the summation of all possible statistical weights of the system:$$Z = \sum S_{i}$$

The partition function is the normalization factor by which the probabilities of the different states of the system are calculated so that the probability for state j is:$$prob\left( statej \right) = S_{j}/Z$$

For our model, the statistical weights of the states of bound unphosphorylated and phosphorylated NICD are:$$\alpha_{up} = \frac{NICD_{up}}{k_{\alpha}}$$$$\alpha_{p} = \frac{NICD_{p}}{k_{\alpha}}$$where $k_{\alpha} = \frac{k_{\alpha}^{-}}{k_{\alpha}^{+}}$ is the dissociation constant of NCM to an SPS site. Thus, the partition function of one binding site is:$$Z = 1 + \alpha_{up} + \alpha_{p}$$

The total number of SPS sites, $N$, is comprised of endogenous SPS sites ($N_{e}$) and synthetic SPS sites ($N_{s}$):$$N = N_{e} + N_{s}$$

Note, $N_{e}$ is an effective number for the cumulative impact of all endogenous sites (i.e. the many weak Notch binding sites within the genome) relative to the effect of the strong SPS sites in the *GBE-SPS* transgenes.

Combining [Equations 9, 10, 11, 12, 13, 14, 15](#equ9 equ10 equ11 equ12 equ13 equ14 equ15){ref-type="disp-formula"} results in the following two equations:$$0 = NICD_{0} - NICD_{up} - \left( {N_{e} + N_{s}} \right)\frac{NICD_{up}}{k_{\alpha} + NICD_{p} + NICD_{up}}\left( k_{p}^{'} - 1 \right)$$$$0 = \left( {N_{e} + N_{s}} \right)\frac{NICD_{up}}{k_{\alpha} + NICD_{p} + NICD_{up}}k_{p}^{'} - NICD_{p}\Gamma_{p}^{'} + \left( {N_{e} + N_{s}} \right)\frac{NICD_{p}}{k_{\alpha} + NICD_{p} + NICD_{up}}\Gamma_{p}^{'}$$

This statistical mechanics approach is based on three main assumptions: (1) The binding dynamics (on and off rates) are much faster than the dynamics determining the level of NICD in the nucleus. This is clearly valid as the DNA binding time scales are of the order of seconds ([@bib25]) and degradation time scales are of the order of minutes to hours. (2) The number of NICD molecules in the nucleus is larger than the number of SPS sites. Since we typically look at a range of NICD concentrations of $10^{2} - 10^{4}$ per nucleus, and a maximum number of SPS sites of 36, this assumption is also justified. (3) For simplicity, we assume that binding to different SPS sites are independent.

We also consider the situation where the nuclear NICD concentration is much higher than the dissociation rate: $\left\lbrack {NICD_{p}} \right\rbrack + \left\lbrack {NICD_{up}} \right\rbrack \gg k_{\alpha}$, namely, that we are in a strong binding regime. Under this assumption, the results are largely independent of the values of $k_{\alpha}$.

We use [Equation (16) and (17)](#equ16 equ17){ref-type="disp-formula"} to solve for $NICD_{p}$, $NICD_{up}$, and $NICD_{tot}$ and obtain their steady state levels for each set of parameters. These steady state solutions were used to plot Figures 4b and 4h (model curves).

### Analysis of the linear regime {#s4-9-1}

Since phosphorylation of NICD by Cdk8 occurs only for bound NICD, it can be assumed that for a low number of SPS sites $NICD_{p},k_{\alpha},\left( {N_{e} + N_{s}} \right) \ll NICD_{up}$. In this regime, [Equations 16 and 17](#equ16 equ17){ref-type="disp-formula"} are approximated by:$$NICD_{up} \cong NICD_{0} - \left( {N_{e} + N_{s}} \right)\left( k_{p}^{'} - 1 \right)$$$$NICD_{p} \cong \left( {N_{e} + N_{s}} \right)\frac{k_{p}^{'}}{\Gamma_{p}^{'}}$$

The total concentration of NICD is then:$$NICD_{tot} \cong NICD_{0} - \left( {N_{e} + N_{s}} \right)k_{p}^{'}\left( {1 - \frac{1}{\Gamma_{p}^{'}} - \frac{1}{k_{p}^{'}}} \right)$$

We now assume the phosphorylation rate of $NICD_{up,b}$ is much faster than the degradation rate of $NICD_{up.ub}$, that is: $k_{p} \gg \Gamma_{up}$. Under this assumption equation (20) becomes:$$NICD_{tot} \cong NICD_{0} - \left( {N_{e} + N_{s}} \right)k_{p}^{'}\left( {1 - \frac{1}{\Gamma_{p}^{'}}} \right)$$

This analysis predicts that the slope in the linear regime is$$slope_{wt} = - k_{p}^{'}\left( {1 - \frac{1}{\Gamma_{p}^{'}}} \right)$$

For mutant *skd* heterozygotes ($skd^{+ / -}$), we expect the phosphorylation rate to change to $k_{p,het}^{'}$. The expression for the total NICD in $skd^{+ / -}$ is then:$$NICD_{tot}^{het} \cong NICD_{0} - \left( {N_{e} + N_{s}} \right)k_{p,het}^{'}\left( {1 - \frac{1}{\Gamma_{p}^{'}}} \right)$$

The ratio of the slopes between the wild type and $skd^{+ / -}$ will simply be:$$\frac{slope_{het}}{slope_{wt}} = \frac{k_{p,het}^{'}}{k_{p}^{'}}$$

If $skd$ is a limiting factor for the formation of the Cdk8 Mediator submodule, it is expected that reducing its copy number from 2 to 1 in $skd^{+ / -}$ would result in halving the Cdk8 phosphorylation activity, that is that $k_{p,het}^{'} = \frac{1}{2}k_{p}^{'}$ of the wild type.

The difference between equations 21 and 23 at $N_{s} = 0$ gives an expression for $N_{e}$:$$N_{e} = \frac{NICD_{tot}\left( N_{s} = 0 \right) - NICD_{tot}^{het}\left( N_{s} = 0 \right)}{\left( {k_{p,het}^{'} - k_{p}^{'}} \right)\left( {1 - \frac{1}{\Gamma_{p}^{'}}} \right)}$$

To check the ratio between wildtype and *skd* het slopes and to estimate $N_{e}$, we performed linear regression on the data for the mean values of *6S-GFP* expression in [Figure 4h](#fig4){ref-type="fig"} using the first 3 points of wildtype data (the fourth point is in the saturated regime) and the 4 points of $skd^{+ / -}$ data. We note that the data is normalized to the mean fluorescence level of *6S-GFP* expression at $N_{s} = 0$, so [Equations 21 and 23](#equ21 equ23){ref-type="disp-formula"} are normalized by $NICD_{tot}\left( N_{s} = 0 \right)$. This normalization factor does not affect the expressions in [Equations 24 and 25](#equ24 equ25){ref-type="disp-formula"} as it cancels out. The errors are estimated using standard error calculation on multivariate expression ([@bib10]).

### Estimation of $k_{p}$ {#s4-9-2}

The slope of the normalized linear fit is given by$$slope_{wt}^{norm} = \frac{slope_{wt}}{NICD_{tot}\left( {N_{s} = 0} \right)} = \frac{k_{p}^{'}\left( {1 - \frac{1}{\Gamma_{p}^{'}}} \right)}{NICD_{0} - N_{e}k_{p}^{'}\left( {1 - \frac{1}{\Gamma_{p}^{'}}} \right)}$$

Which leads to the following expression for $k_{p}$$$k_{p} = \frac{NICD_{0}\Gamma_{up}}{\left( {- \frac{1}{slope_{wt}^{norm}} + N_{e}} \right)\left( {1 - \frac{\Gamma_{up}}{\Gamma_{p}}} \right)}$$

This expression allows estimating $k_{p}$ for different parameter values. We use the calculated values of $slope_{wt}^{norm}$ and $N_{e}$. We estimate the steady state amount of NICD in the nucleus, $NICD_{0}$, ranges between 100 (below that, the concentration is unlikely to activate multiple Notch targets in the nucleus) and 10,000. The upper limit is based on the fact that bicoid concentration is about 10,000 molecules/nucleus ([@bib27]). Since endogenous NICD concentration is so small that it is notoriously hard to detect it in the nucleus using standard imaging techniques ([@bib12]), we estimate that it is not larger than the typical concentration of Bicoid. The estimated range of unphosphorylated NICD is between $\frac{1}{30}{min}^{- 1}$ to $\frac{1}{1000}{min}^{- 1}$ corresponding to half-lives of the range of 0.5-16 hours, which fits the typical half-lives of proteins. Note, that the analysis in [Figure 3F](#fig3){ref-type="fig"} shows a half-life of about $120min$ in cell culture. Finally, since we assume that $\frac{\Gamma_{up}}{\Gamma_{p}} \ll 1$ the exact value of $\Gamma_{p}$ has only a weak effect on the values of $k_{p}$. For the calculation we take it to be $\Gamma_{p} = \frac{1}{8}{min}^{- 1}$ which is close to the rate observed in *Drosophila* cell culture ([@bib30]).

### Dynamic simulations {#s4-9-3}

To study the dynamics of NICD in the nucleus, we numerically solved the dynamic equations corresponding to [Equations 16 and 17](#equ16 equ17){ref-type="disp-formula"}:$$\frac{d}{dt}NICD_{up} = NICD_{0} - NICD_{up} - \left( {N_{e} + N_{s}} \right)\frac{NICD_{up}}{k_{\alpha} + NICD_{p} + NICD_{up}}\left( k_{p}^{'} - 1 \right)$$$$\frac{d}{dt}NICD_{p} = \left( {N_{e} + N_{s}} \right)\frac{NICD_{up}}{k_{\alpha} + NICD_{p} + NICD_{up}}k_{p}^{'} - NICD_{p}\Gamma_{p}^{'} + \left( {N_{e} + N_{s}} \right)\frac{NICD_{p}}{k_{\alpha} + NICD_{p} + NICD_{up}}\Gamma_{p}^{'}$$

The equations were solved using ODE solver in MATLAB, with initial conditions $NICD_{up}\left( {t = 0} \right) = NICD_{p}\left( {t = 0} \right) = 0$. The values of parameters used for the simulations are given in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. For simulating wildtype cells, we assumed $N_{s} = 0$ and $N_{e} = 5.4$. For simulating $N^{+ / -}$ cells, we assumed $P_{NICD}^{Nhet} = \frac{1}{2}P_{NICD}^{wt}$. For simulating cells with two copies of 6SG, we assumed $N_{s} = 12$.

Parameter values {#s4-10}
----------------

FigureParameter values used[Figure 4B](#fig4){ref-type="fig"}$NICD_{0} = 2000\frac{\#}{nuc}$, $\Gamma_{up} = \frac{1}{120}{min}^{- 1}$,$\Gamma_{p} = \frac{1}{8}{min}^{- 1}$, $k_{p} = 1,0.5,0.25{min}^{- 1}$[Figure 4H](#fig4){ref-type="fig"}$NICD_{0} = 2000\frac{\#}{nuc}$, $\Gamma_{up} = \frac{1}{120}{min}^{- 1}$, $\Gamma_{p} = \frac{1}{8}{min}^{- 1}$, $slope_{wt} = - 0.0294$, $slope_{skd} = \frac{1}{2}slope_{wt}$, $N_{e} = 5.4$, $k_{p}^{wt} = \frac{NICD_{0}\Gamma_{up}}{\left( {- \frac{1}{Slope_{wt}} + N_{e}} \right)\left( {1 - \frac{\Gamma_{up}}{\Gamma_{p}}} \right)}$, $k_{p}^{skd} = \frac{NICD_{0}\Gamma_{up}}{\left( {- \frac{1}{Slope_{skd}} + N_{e}} \right)\left( {1 - \frac{\Gamma_{up}}{\Gamma_{p}}} \right)}$[Figure 4I](#fig4){ref-type="fig"}$NICD_{0} = 100 - 10,000\frac{\#}{nuc}$, $\Gamma_{up} = \frac{1}{30} - \frac{1}{1000}{min}^{- 1}$,$\Gamma_{p} = \frac{1}{8}{min}^{- 1}$, $slope_{wt} = - 0.0294$, $N_{e} = 5.4$, $k_{p}^{wt} = \frac{NICD_{0}\Gamma_{up}}{\left( {- \frac{1}{Slope_{wt}} + N_{e}} \right)\left( {1 - \frac{\Gamma_{up}}{\Gamma_{p}}} \right)}$[Figure 4K](#fig4){ref-type="fig"}$NICD_{0}^{wt} = 2000\frac{\#}{nuc}$, $NICD_{0}^{Nhet} = 1000\frac{\#}{nuc}$, $\Gamma_{up} = \frac{1}{120}{min}^{- 1}$, $\Gamma_{p} = \frac{1}{8}{min}^{- 1}$, $slope_{wt} = - 0.0294$, $N_{e} = 5.4$, $k_{p}^{wt} = \frac{NICD_{0}\Gamma_{up}}{\left( {- \frac{1}{Slope_{wt}} + N_{e}} \right)\left( {1 - \frac{\Gamma_{up}}{\Gamma_{p}}} \right)}$, $N_{s} = 12$ (for 2xG6S-LacZ)[Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}For A, same parameters as [Figure 4k](#fig4){ref-type="fig"}\
B: $NICD_{0}^{wt} = 200\frac{\#}{nuc}$, C: $NICD_{0}^{wt} = 20000\frac{\#}{nuc}$\
D: $\Gamma_{up} = \frac{1}{30}{min}^{- 1}$, E: $\Gamma_{up} = \frac{1}{1000}{min}^{- 1}$\
F: $\Gamma_{p} = \frac{1}{4}{min}^{- 1}$, G: $\Gamma_{p} = \frac{1}{30}{min}^{- 1}$

Lead contact and materials availability {#s4-11}
---------------------------------------

All materials used in this study will be made freely available. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Brian Gebelein ([brian.gebelein\@cchmc.org](https://www.cincinnatichildrens.org/research/divisions/d/dev-biology/labs/gebelein)).

Code availability {#s4-12}
-----------------

All simulation codes are available in the GitHub repository at <https://github.com/OhadGolan/NICD-concentration-in-the-nucleus-as-by-binding-site-coupled-NICD-degradation.git> ([@bib24]; copy archived at <https://github.com/elifesciences-publications/NICD-concentration-in-the-nucleus-as-by-binding-site-coupled-NICD-degradation/tree/master>).
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Overall, this is an interesting manuscript with novel and important results. A number of Notch pathway components show significant haploinsufficient phenotypes in animal models and in human patients. However, the basis for tissue-specific phenotypes observed in these diseases and their phenotypic variability is not fully understood. The current work provides a new potential mechanism that might contribute to some aspect of phenotypic variability in these diseases.

Essential revisions:

Some sections of the manuscript are not well explained, and some conclusions do not seem to be fully supported by the data. Moreover, although the idea that duration of signaling determines which cell types are sensitive to SPS sites is appealing, it is only one of the possibilities.

1\) Please describe the EMSA data shown in Figure 1 and Figure 1---figure supplement 1 and provide your conclusion. Currently, the EMSA data is not discussed in the Results section. The cooperative binding to SPS seems to be clear for the mammalian complex but not as much for the fly complex. Is it known whether the complex binds the 1x SPS better/stronger that 2x CSL? In other words, have people done competition assays with cold 2x CSL probe in the 1x SPS EMSA and vice versa? Experiments along this line or referring to literature about relative affinity of the RBPJ/Notch/Mam complex for tandem single versus SPS sites might provide clues for the observed difference between single and SPS sites.

2\) Subsection "Enhancers with specific TF binding sites can induce a tissue-specific *Notch* phenotype", \"The relative order of GBE and SPS did not matter (Figure 1---figure supplement 2E-F,H)\": The data shown in this figure do not support this conclusion. Moreover, no statistics is provided. On the other hand, comparison of Figures 1J and 1K supports this conclusion. Are the quantifications shown in Figure 1---figure supplement 2H accurate? (especially the top two genotypes)

3\) How specific is Senexin-A for CDK8? It seems that the only direct evidence used to link mammalian NICD and CDK8 in the manuscript is this compound. If Senexin-A has not been shown to be highly specific for CDK8, knock-down or knockout of CDK8 in a mammalian cell line should be considered to make the link stronger. This is important for two reasons: (a) No direct evidence has been provided for decreased stability of the fly NICD in animals harboring 6SG transgenes; (b) Removing one copy of Cdk8 did not significantly change the wing margin phenotype of *N^+/-^* animals, unlike other components of the CKM complex.

4\) In subsection "Cdk8 induces Notch turnover independent from transcription activation" the authors state that \"...we found that NICD was stabilized in both mammalian OT11 cells deficient for RPBJ and mK4 cells deficient for three mastermind-like proteins. While the data for the OT11 cells is convincing (Figure 3H), the data for mK4 cells in Figure 3---figure supplement 2 lack a control comparison. In subsection "Cdk8 induces Notch turnover independent from transcription activation", the authors suggest that the upper band represents NICD with a posttranslational modification. Can the authors show that there is decreased ubiquitination of NICD in Rbpj knockout cells or in cells treated with Senexin-A? Alternatively, since phosphorylation is a key aspect of the mathematical modeling in the manuscript, it might be worth testing whether treating the cell lysate from control cells with a phosphatase increases the mobility of NICD in the gel. Also, please mention what the open and filled arrowheads represent in Figure 3F (perhaps in the legend).

5\) In Figure 4J, in the *H^1/+^* genetic background, the removal of one copy of cycC seems to significantly decrease macrochaetae (at p = 8.7X10-3), yet the authors make no mention of this data, stating only that \"removing and allele of *skd* or *cdk8* did not significantly alter macrochaetae formation\". Although the data supports their conclusion that macrochaetae are relatively unaffected by these genetic manipulations, one wonders if there is any biological significance to the cycC data in this context?

6\) Subsection "Altered NICD degradation sensitizes tissues requiring long duration signals", \"We assume that N heterozygotes lower NICD production by one half without impacting NICD.\": This assumption is likely to be too simplistic and cell type dependent. Given the importance of *cis*-inhibitory interactions in the Notch haploinsufficient phenotypes in the wing, depending on the relative ligand-to-Notch levels in each context, this number might be lower or higher than one half. In fact, the reason Notch haploinsufficient phenotypes are sensitive to the presence of SPS in some contexts but not others might be the relative contribution of *cis*-inhibition in each context (and/or the relative levels of ligands to Notch in each context). A simplistic example will be to have 10 Notch molecules and 4 ligand molecules in a given cell. Normally, 6 Notch molecules will be competent to generate NICD in this cell. Upon removal of one copy of Notch, only 1 Notch molecule might be available to generate NICD in this cell.

7\) Discussion section, paragraphs 1-2: Is there an estimate for the number of SPS sites in the fly genome? The authors mention that Severson et al., suggested that SPS sites contribute to the regulation of about a third of direct Notch1 targets in T-cells. If there are so many SPS sites scattered in the genome, why adding 12 SPS sites can have such a dramatic effect? Does this suggest that the endogenous SPS sites are rarely close to the binding sites of pioneer factors? The mathematical modeling predicted that the contribution of endogenous SPS sites is equivalent to \~5 active synthetic SPS sites. It is worth adding some sentences to the Discussion section to better explain the significance of their findings in the regulation of endogenous Notch signaling, in a wild-type background and in contexts of haploinsufficiency for Notch or its ligands.

8\) Discussion section, paragraph 3: In my opinion, linking Notch pathway duration to the observed differences is rather speculative. Although wing margin development takes longer than lateral inhibition, it is not a simple sending-receiving situation that is extended for two days. The direction of signaling and the identity and level of ligands used during wing margin development evolve over time. Moreover, there are other differences between wing margin formation and macrochaetae lateral inhibition. For example, both Delta and Serrate play key and non-redundant roles in wing margin formation, and Serrate loss-of-function phenotype is more severe in the wing margin than the Delta loss-of-function phenotype (for example, Lee et al., 2017). However, loss of Serrate by itself does not have any macrochaetae phenotype, and Serrate only contributes redundantly to macrochaetae lateral inhibition (Pistouli and Delidakis, 2005). Similarly, Serrate only plays a redundant role during wing vein development (Zeng et al., 1998), and based on Figure 4H, even 4 copies of 6SG do not recapitulate the wing vein expansion phenotype of Notch\[+/-\] animals. The authors should consider modifying this paragraph to acknowledge that Notch signaling duration is just one possibility.

9\) Subsection "Cdk8 induces Notch turnover independent from transcription activation", about the conclusion that removing an allele of each gene of the Cdk8-kinase module significantly suppressed the penetrance and severity of the 6SG-induced wing nicking: Although the data shown in Figure 3 support this conclusion, there is a dramatic variation in the penetrance of wing nicking phenotypes caused by 2 copies of 6SG-lacZ among the figures (compare 1J/1K, 1-S2H, and 2F with 3A). The integration sites used in this study seem to be on a *yw* background. Was the X chromosome crossed out and replaced with a different genetic background when establishing the stocks?

10\) Figure 4D-G: Although a subset cells show loss of Cut-positive cells, there seems to be a broadening of Cut expression across the dorso-ventral boundary in all three genotypes with (G6S)n-lacZ. Are these images full projection views? Do the authors have an explanation for this observation (assuming the images are representative for the Cut expression in these genotypes)?

11\) Subsection "Quantitative analysis of Enhancer binding site induced Notch turnover", \"We found that GFP levels decreased as a function of added GBE-SPS sites\": Potentially related to the above note on Figure 4D-G, although addition of two or three cassettes of G6S clearly results in decreased GFP expression from S-GFP, it appears that the GFP expression domain is broader, with somewhat brighter signal upon addition of one G6S site. Please make sure representative images are shown that match the quantification in 4H. Whether the wing margin region becomes broader in all of these transgenes or not remains an open question. It is worth noting that decreasing CKM gene dosage also affected macrochaetae numbers in the opposite direction of what was expected. Is any other component of the Notch pathway known to be regulated by the CKM complex? For example, if Delta is also a target, a change in the level of Delta might explain both phenotypes (trans-Delta in the case of macrochaetae, cis-Delta in the case of wing margin).

12\) The mathematical model used to describe the dynamics of NICD in the cells assumes that dephosphorylation of NICD is absent. While there is no evidence that dephosphorylation of NICD occurs and even if it does there would either be little effect on the model (if dephosphorylation rates were low) or add an additional complexity unnecessary to the model and beyond the scope of the present study, it is an inherent assumption of the model and should be stated as such.

10.7554/eLife.53659.sa2

Author response

> Essential revisions:
>
> Some sections of the manuscript are not well explained, and some conclusions do not seem to be fully supported by the data. Moreover, although the idea that duration of signaling determines which cell types are sensitive to SPS sites is appealing, it is only one of the possibilities.

We revised the text throughout the manuscript to better explain our experimental results and conclusions with each change highlighted under the relevant specific points raised below. Moreover, we acknowledge that while our data is consistent with the duration model, other factors may contribute to the different sensitivities observed in the wing versus macrochaetae tissues. Hence, we added several sentences in the Discussion section highlighting that additional tissue-specific factors besides signal duration could contribute to the differences in phenotypes observed between the wing and macrochaetae.

> 1\) Please describe the EMSA data shown in Figure 1 and Figure 1---figure supplement 1 and provide your conclusion. Currently, the EMSA data is not discussed in the Results section. The cooperative binding to SPS seems to be clear for the mammalian complex but not as much for the fly complex. Is it known whether the complex binds the 1x SPS better/stronger that 2x CSL? In other words, have people done competition assays with cold 2x CSL probe in the 1x SPS EMSA and vice versa? Experiments along this line or referring to literature about relative affinity of the RBPJ/Notch/Mam complex for tandem single versus SPS sites might provide clues for the observed difference between single and SPS sites.

We apologize for this omission. We added several sentences to the Results section to describe the EMSA results and conclusions derived from this line of experimentation (see subsection "Enhancers with specific TF binding sites can induce a tissue-specific *Notch* phenotype" of the revised submission).

To address the question raised about whether the 1xSPS probe is bound better/stronger than the 2xCSL probe by NCM complexes, we performed new EMSA experiments in which the 1xSPS and 2xCSL probes were differentially labeled and added to the same binding reaction with either the mammalian or fly proteins (Figure 1B-C). Hence, direct comparisons can be made in regard to the binding characteristics of the Su(H)/RBPJ transcription factors and the NICD/MAM co-activators to these two probes. These data show that in the absence of co-activators, the 2xCSL probe is bound slightly better by the Su(H)/RBPJ transcription factors than the 1xSPS probe. However, in the presence of NICD/Mam, the 1xSPS is preferentially bound by both the fly and mammalian proteins over the 2xCSL. We describe these results in the modified Results section and included the fly protein EMSAs in Figure 1C rather than in the figure supplement.

We also agree that the mouse proteins appear to be more cooperative than the fly proteins in our EMSAs and we describe and show this observation in Figure 1---figure supplement 1. We decided not to include it in the main text for two reasons: First, our main goal was to test if the fly proteins, which to our knowledge were never tested on SPS sites by EMSAs, generally behave like the mouse proteins. Our data clearly show that the fly proteins do indeed bind cooperatively to the 1xSPS site, but not to the 2xCSL sites. Second, while the main driver of NICD-induced cooperativity is a dimer interface in the Notch ANK domains, which is found in both species (see the data in https://doi.org/10.1101/2020.02.13.948224) slight differences in the polypeptides used in EMSA may impact the degree of cooperativity. Moreover, these differences may reflect the challenge in purification of the NICD and Mam proteins. Thus, we cannot be certain that the differences in cooperativity observed between the mouse and fly proteins in this assay are biologically meaningful.

> 2\) Subsection "Enhancers with specific TF binding sites can induce a tissue-specific Notch phenotype", \"The relative order of GBE and SPS did not matter (Figure 1---figure supplement 2E-F,H)\": The data shown in this figure do not support this conclusion. Moreover, no statistics is provided. On the other hand, comparison of 1J and 1K supports this conclusion. Are the quantifications shown in Figure 1---figure supplement 2H accurate? (especially the top two genotypes)

We agree with the reviewers that we overstated this conclusion and reworded the sentence as follows: "i) The *6SG-lacZ* caused notched wings when inserted in another locus and regardless of the order of GBE and SPS, although with differences in penetrance and severity" (subsection "Enhancers with specific TF binding sites can induce a tissue-specific *Notch* phenotype"). We also added statistical tests to Figure 1---figure supplement 2.

The reviewers are also correct that differences in penetrance and severity are sometimes observed between experiments and these differences arise from two sources: First, some differences in penetrance and severity can be attributed to the insertion location: flies with (2 copies in 51C) *vs* (2 copies in 86Fb) *vs* (1 copy in 51C and 1 copy in 86Fb) vary in penetrance/severity. These data are shown and described in Figure 1---figure supplement 2 and statistical tests are now included in this figure to account for the differences in penetrance/severity. Second, we found that the severity/penetrance can vary depending upon environmental changes (i.e. food quality and overcrowding). To deal with this source of variability, all experiments assessing wing notching within each Figure panel were performed with appropriate controls using food made from the same batch and similar fly densities to avoid environmental confounders. We included this information in the Materials and methods section of the paper to better explain our experimental protocol.

> 3\) How specific is Senexin-A for CDK8? It seems that the only direct evidence used to link mammalian NICD and CDK8 in the manuscript is this compound. If Senexin-A has not been shown to be highly specific for CDK8, knock-down or knockout of CDK8 in a mammalian cell line should be considered to make the link stronger. This is important for two reasons: (a) No direct evidence has been provided for decreased stability of the fly NICD in animals harboring 6SG transgenes; (b) Removing one copy of Cdk8 did not significantly change the wing margin phenotype of N^+/-^ animals, unlike other components of the CKM complex.

Senexin A was first described as an optimized inhibitor for CDK8/CDK19 paralogs and the authors claimed that it showed "striking selectivity" (Porter et al., 2012). Senexin A has since been used by multiple other research groups (Galbraith et al., 2017; Wang et el., 2017; Song el al., 2019). To further address this concern, we performed the same half-life measurement with SEL120-34A, another CDK8/CDK19 inhibitor, which was shown to be highly selective and efficient for CDK8/CDK19 (Rzymski et al., 2017). Since Senexin A and SEL120-34A are structurally distinct, they are unlikely to share the same targets other than CDK8/CDK19. Importantly, we observed a similar result with SEL120-34A as to that we observed with Senexin A -- inhibitor treatment prolonged NICD half-life. These new findings are described in the Results section and the data are now included in Figure 3---figure supplement 2B and 2D.

For the finding that removing one copy of Cdk8 did not significantly change the wing margin phenotype of *N^+/-^* animals, we would like to point out that catalytic components of multi-subunit enzymes are often not rate limiting factors. In fact, a previous research study found that enzymes, in general, were depleted from the list of haploinsufficiency genes, whereas structural/regulatory proteins that form macromolecular complexes were enriched in haploinsufficiency genes (Kondrashov, et al., 2004). Hence, it is not surprising that CDK8 is not the rate limiting factor in this genetic assay. Instead, the wing phenotype is far more sensitive to the gene dose of the structural/regulatory proteins encoded by the *med12 (kto), med13 (skd*) and the *cycC* genes, which collectively form the CDK8-kinase module with Cdk8. Moreover, this finding is in agreement with prior reports that cycC (CCNC) has been reported to be a haploinsufficient tumor suppressor (Li et al., 2014). We make these points more clearly in the revised Results section and Discussion section.

> 4\) In subsection "Cdk8 induces Notch turnover independent from transcription activation" the authors state that \"...we found that NICD was stabilized in both mammalian OT11 cells deficient for RPBJ and mK4 cells deficient for three mastermind-like proteins. While the data for the OT11 cells is convincing (Figure 3H), the data for mK4 cells in Figure 3---figure supplement 2 lack a control comparison. In subsection "Cdk8 induces Notch turnover independent from transcription activation", the authors suggest that the upper band represents NICD with a posttranslational modification. Can the authors show that there is decreased ubiquitination of NICD in Rbpj knockout cells or in cells treated with Senexin-A? Alternatively, since phosphorylation is a key aspect of the mathematical modeling in the manuscript, it might be worth testing whether treating the cell lysate from control cells with a phosphatase increases the mobility of NICD in the gel. Also, please mention what the open and filled arrowheads represent in Figure 3F (perhaps in the legend).

To address these concerns, we did the following: First, we added the control Western blot for the MAML knockout cells (Figure 3---figure supplement 2E). Second, we performed a Western blot using mK4 cells treated with SEL120-34A and found that this CDK8/CDK19 inhibitor resulted in both increased NICD stability and mobility, consistent with reduced NICD phosphorylation (Figure 3---figure supplement 2D). Third, we treated the protein lysates from mK4 cells with Calf intestinal phosphatase (CIP) and confirmed that the slower migrating (upper) band of NICD is phosphorylation-dependent (Figure 3---figure supplement 2F). Fourth, we added the following description for the arrows in the figure legends of Figure 3 and Figure 3---figure supplement 2: "Open arrow denotes post-translationally modified NICD and closed arrow denotes unmodified NICD."

> 5\) In Figure 4J, in the H^1/+^ genetic background, the removal of one copy of cycC seems to significantly decrease macrochaetae (at p = 8.7X10-3), yet the authors make no mention of this data, stating only that \"removing and allele of skd or cdk8 did not significantly alter macrochaetae formation\". Although the data supports their conclusion that macrochaetae are relatively unaffected by these genetic manipulations, one wonders if there is any biological significance to the cycC data in this context?

To address this concern, we provided a more thorough description of the macrochaetae results generated in conjunction with the compound heterozygotes containing either a *Notch* or *Hairless* allele with mutations in the CDK8 kinase module (*cdk8, cycC, kto* (MED12), and *skd* (MED13)). In particular, we added the following statements in the Results section:

"However, we did find that removing an allele of cycC had a small, but significant impact on macrochaetae formation in H;cycC compound heterozygotes. \[...\] Nevertheless, these data suggest that macrochaetae development in general is relatively insensitive to changes in CKM gene dose in comparison to Notch dependent wing margin phenotypes."

In addition, we also changed the Discussion section to include that the CDK8 kinase module is likely to have additional targets outside of the Notch signaling pathway. Hence, we cannot exclude that additional tissue-specific CDK8 module targets may contribute to the observed phenotypes.

> 6\) Subsection "Altered NICD degradation sensitizes tissues requiring long duration signals", \"We assume that N heterozygotes lower NICD production by one half without impacting NICD.\": This assumption is likely to be too simplistic and cell type dependent. Given the importance of cis-inhibitory interactions in the Notch haploinsufficient phenotypes in the wing, depending on the relative ligand-to-Notch levels in each context, this number might be lower or higher than one half. In fact, the reason Notch haploinsufficient phenotypes are sensitive to the presence of SPS in some contexts but not others might be the relative contribution of cis-inhibition in each context (and/or the relative levels of ligands to Notch in each context). A simplistic example will be to have 10 Notch molecules and 4 ligand molecules in a given cell. Normally, 6 Notch molecules will be competent to generate NICD in this cell. Upon removal of one copy of Notch, only 1 Notch molecule might be available to generate NICD in this cell.

As pointed out by the reviewer, we have indeed used the simplified assumption that NICD production is halved for *Notch* heterozygous animals. The main point was to show that the reduction in production affects both long duration and short duration processes. As the reviewer pointed out, *cis*-inhibition is expected to reduce NICD levels in the *Notch* heterozygotes even more, and if such a mechanism impacts one tissue to a higher degree than another, it would potentially make that tissue more sensitive to changes in *Notch* gene dose. We now added several sentences addressing the potential effect of *cis*-inhibition, and how it, and other potential tissue-specific factors, may impact the underlying parameters that contribute to the duration model (Discussion section).

> 7\) Discussion section, paragraphs 1-2: Is there an estimate for the number of SPS sites in the fly genome? The authors mention that Severson et al., suggested that SPS sites contribute to the regulation of about a third of direct Notch1 targets in T-cells. If there are so many SPS sites scattered in the genome, why adding 12 SPS sites can have such a dramatic effect? Does this suggest that the endogenous SPS sites are rarely close to the binding sites of pioneer factors? The mathematical modeling predicted that the contribution of endogenous SPS sites is equivalent to \~5 active synthetic SPS sites. It is worth adding some sentences to the Discussion section to better explain the significance of their findings in the regulation of endogenous Notch signaling, in a wild-type background and in contexts of haploinsufficiency for Notch or its ligands.

To address this concern, we have added a paragraph in the Discussion section describing the current literature in regards to numbers of SPS sites in the genome. In this paragraph, we discuss that while the number of functional SPS sites in the *Drosophila* genome has not been accurately determined, we do have estimates from mammalian cells. Moreover, we also have some estimates for the number of Su(H) binding loci in a *Drosophila* wing cell line, although this study didn't differentiate CSL vs. SPS sites. In addition to incorporating this information into the discussion, we also discussed the possibility that concentrating the SPS sites at a specific locus may have an "avidity" impact such that any NICD molecule recruited to the locus has a very high probability of being marked for degradation. By integrating these data into the manuscript, we believe it puts our finding that transgenes with as few as 12 SPS sites can induce phenotypes into a better context relative to the entire endogenous genome.

> 8\) Discussion section, paragraph 3: In my opinion, linking Notch pathway duration to the observed differences is rather speculative. Although wing margin development takes longer than lateral inhibition, it is not a simple sending-receiving situation that is extended for two days. The direction of signaling and the identity and level of ligands used during wing margin development evolve over time. Moreover, there are other differences between wing margin formation and macrochaetae lateral inhibition. For example, both Delta and Serrate play key and non-redundant roles in wing margin formation, and Serrate loss-of-function phenotype is more severe in the wing margin than the Delta loss-of-function phenotype (for example, Lee et al., 2017). However, loss of Serrate by itself does not have any macrochaetae phenotype, and Serrate only contributes redundantly to macrochaetae lateral inhibition (Pistouli and Delidakis, 2005). Similarly, Serrate only plays a redundant role during wing vein development (Zeng et al., 1998), and based on Figure 4H, even 4 copies of 6SG do not recapitulate the wing vein expansion phenotype of Notch\[+/-\] animals. The authors should consider modifying this paragraph to acknowledge that Notch signaling duration is just one possibility.

We agree that the proposed duration model is correlative by nature and it is difficult to definitively test the model (i.e. alter signal duration) in the wing margin and macrochaetae. Hence, we expanded the Discussion section to point out that while our data is consistent with the duration model, other tissue-specific factors and parameters may also contribute to the observed differences in sensitivity between the wing margin and macrochaetae.

> 9\) Subsection "Cdk8 induces Notch turnover independent from transcription activation", about the conclusion that removing an allele of each gene of the Cdk8-kinase module significantly suppressed the penetrance and severity of the 6SG-induced wing nicking: Although the data shown in Figure 3 support this conclusion, there is a dramatic variation in the penetrance of wing nicking phenotypes caused by 2 copies of 6SG-lacZ among the figures (compare 1J/1K, 1-S2H, and 2F with 3A). The integration sites used in this study seem to be on a yw background. Was the X chromosome crossed out and replaced with a different genetic background when establishing the stocks?

As for the variability between experiments, please see our response to point \#2 above regarding two sources of phenotype variability. First, while the *6SG-lacZ* transgenes induce wing notching phenotypes regardless of chromosomal integration site, the insertion location can impact the penetrance and severity of the phenotype. Thus, the data in Figure 2F (*6SG-lacZ-51C/6SG-lacZ-51C*) and Figure 3A (*6SG-lacZ-51C/+; 6SG-lacZ-86Fb/+*) are not comparable since the two alleles of *6SG-lacZ* are on different chromosomes, and we found that flies with *6SG-lacZ-51C/+; 6SG-lacZ-86Fb/+* have a higher wing-phenotype penetrance than flies with either *6SG-lacZ-51C/6SG-lacZ-51C* or *6SG-lacZ-86Fb/6SG-lacZ-86Fb* (Figure 1---figure supplement 2H). Second, food quality and fly density can impact the penetrance and severity of the wing nicking phenotype observed, and we described both this result and how we addressed it in point \#2 above. As for the X chromosome, all of our transgenes, including the GBE-CSL reporters, the GBE alone reporters, and the SPS alone reporters that do not induce phenotypes, were created and tested in an identical manner as the transgenes containing the SPS sites. Moreover, we always used *yw* as our control, even when crossing with the *Hairless* and *Notch* heterozygous animals. Given that the *yw* X chromosome never showed phenotypes on its own, nor with any of the other reporters except those with GBE-SPS or when crossed to *Notch* heterozygous animals, we think that it is highly unlikely to contribute in any meaningful way to the observed phenotypes.

> 10\) Figure 4D-G: Although a subset cells show loss of Cut-positive cells, there seems to be a broadening of Cut expression across the dorso-ventral boundary in all three genotypes with (G6S)n-lacZ. Are these images full projection views? Do the authors have an explanation for this observation (assuming the images are representative for the Cut expression in these genotypes)?

The images in Figure 4D-G were taken as Z-stacks before being max-projected. To address this concern, we carefully analyzed all of the wing disc data and found that while the width of the Cut-expressing cells does vary from wing disc to wing disc, we observe similar variation in all genotypes. Also, see our response to the related point 11 below.

> 11\) Subsection "Quantitative analysis of Enhancer binding site induced Notch turnover", \"We found that GFP levels decreased as a function of added GBE-SPS sites\": Potentially related to the above note on Figure 4D-G, although addition of two or three cassettes of G6S clearly results in decreased GFP expression from S-GFP, it appears that the GFP expression domain is broader, with somewhat brighter signal upon addition of one G6S site. Please make sure representative images are shown that match the quantification in 4H. Whether the wing margin region becomes broader in all of these transgenes or not remains an open question. It is worth noting that decreasing CKM gene dosage also affected macrochaetae numbers in the opposite direction of what was expected. Is any other component of the Notch pathway known to be regulated by the CKM complex? For example, if Delta is also a target, a change in the level of Delta might explain both phenotypes (trans-Delta in the case of macrochaetae, cis-Delta in the case of wing margin).

To address the concern regarding the GFP levels and pattern in the wing discs shown in Figure 4D-G, we reanalyzed the data and selected new images that are representative of GFP levels, pattern, and the width of the Cut expression domain. While looking at all of the discs analyzed in this experiment, we did notice variation in the width of Cut expression domain between imaginal discs. However, besides observing gaps in the Cut expression domain for those flies carrying 6, 12, or 18 *GBE-SPS* sites (marked by arrowheads in Figure 4E-G), the variation was similar between genotypes. Moreover, it is important to point out that all of the data collected from each imaginal disc was included in the quantified data shown in Figure 4H, as each dot on the graph is the average GFP intensity in the Cut-positive cells from a single wing imaginal disc and none of the discs were excluded from this analysis.

The reviewer also raised a second point: Is any other component of the Notch pathway known to be regulated by the CKM complex? To our knowledge, CKM activity is restricted to the nucleus and does not modify the Delta ligand or the unprocessed Notch receptor. However, CKM activity is known to phosphorylate other transcriptional regulators including Mastermind, CycC, Med12, and Med13. Taking these potential targets into account, removing an allele of CKM components would still be predicted to increase Notch signal strength, which is consistent with our current model. In addition, to these points, we also included a statement that we cannot exclude the possibility that CKM activity alters additional transcriptional regulatory proteins, and that they could contribute to the observed phenotypes. We make these points clearer in the modified Discussion section.

> 12\) The mathematical model used to describe the dynamics of NICD in the cells assumes that dephosphorylation of NICD is absent. While there is no evidence that dephosphorylation of NICD occurs and even if it does there would either be little effect on the model (if dephosphorylation rates were low) or add an additional complexity unnecessary to the model and beyond the scope of the present study, it is an inherent assumption of the model and should be stated as such.

We agree with the reviewer that adding additional complexity to the model is beyond the scope of the present study. We have specified in the new version that we assume no dephosphorylation of NICD is considered in the model in the Results section.

[^1]: These authors contributed equally to this work.
